The difference in COVID-19 death rates between white people and black, Asian and minority ethnic (BAME) people in the UK is shocking. One recent report found that, between the beginning of February and the end of April 2020, black people in England were 71% more likely than white people to die from COVID-19. And Asian people were 62% more likely.

This disparity has led to an inquiry by Public Health England and funding for urgent academic research into the issue. We expect many factors to be involved, including the disadvantages that BAME people face due to greater chances of poverty and health issues.

But its important that we examine whether there may also be a genetic component to the problem in order to fully understand whats going on. My colleagues and I are conducting research among frontline healthcare workers to try to see if there are any innate differences in the way different peoples immune systems respond to this specific virus, including genetic differences that may be associated with ethnicity.

Researchers have identified a greater chance of dying from COVID-19 among BAME people in several countries aside from the UK, including Norway and the US. There are many social reasons why ethnic minorities may generally be more vulnerable to disease, including a greater chance of malnutrition, more exposure to pollution due to where they live, or greater likelihood of working in less healthy environments.

Inequality and poverty also play a role in the fact that BAME people are more likely to suffer conditions that we know are linked to a greater chance of dying from COVID-19, such as diabetes and heart disease.

Initial data suggests that BAME healthcare workers are more likely to die from COVID-19 than their white colleagues. British Medical Association research has found that BAME doctors are twice as likely as white doctors to feel pressured into working with inadequate PPE when they are at risk of infection. And they are twice as likely not to feel confident enough to raise concerns about workplace safety.

However, all these established facts alone dont seem to explain why the risks of COVID-19 vary between different ethnic groups and are lowest among white people. This is particularly the case when we compare it with other forms of viral pneumonia that do not lead to such a difference.

The study that found BAME people in England were more likely to die from the disease accounted for differences in some underlying health conditions that are strongly linked to social issues, suggesting these werent the main factor. But the preliminary results from another study suggest ethnic minorities arent more likely to die once other factors linked to deprivation are taken into account.

To clarify this issue, its important to examine whether there may be some genetic component that predisposes ethnic minorities to a higher risk to COVID-19, while still recognising the critical role of other factors.

The way peoples immune systems work depends on genetic factors, not just environmental and social ones. There are effectively two parts to our immune systems. One is the part that produces antibodies, called the adaptive immune system. When our body has never seen a virus before, it can take several days for it to produce them, which is why some people get sick in the first place.

We also have an innate immune system that acts before our body has had time to make antibodies. This system is strong in children and young people, but not very good after the age of 65. This is likely to be one reason why older people are at higher risk of dying of COVID-19.

When a virus like the coronavirus SARS-CoV-2 enters a cell, molecules called toll-like receptors, or TLRs, alert the immune system that something potentially harmful is present. Interestingly, many of the bodys TLRs that can detect viruses come from genetic instructions found in the X chromosome, for which men have only one copy and women two.

We know that women can have a more effective innate immune response to other viruses such as HIV than men, and that oestrogen, the female hormone, enhances this type of immune response. We also know that women are less likely to die from COVID-19 than men.

Just as there are variations in DNA that are responsible for the differences in response of immune cells between the sexes, there can also be variations between people of different ethnic backgrounds. For example, the amount and type of genes that immune cells produce when the TLR-virus pathway is stimulated, are very different between people of African and of European origin.

This is not surprising, because we know that human populations from different parts of the planet have had to adapt to different types of infections. Ethnic differences in the risk to other respiratory viral diseases have been linked to genetic variation, and these variants are different in BAME groups and white people in these same pathways. However, the role of ethnicity in genetic susceptibility to viral diseases is still controversial.

We want to see if it could be a factor in the higher rate of BAME deaths from COVID-19. To do this, we are taking blood from frontline healthcare workers of a variety of ethnic backgrounds, assessing DNA differences and measuring the various substances the samples contain. The results could indicate if differences in the innate immune systems of BAME groups result in higher risk of developing severe COVID-19.

If there is some genetic element to the different death rates from COVID-19 between ethnic groups, its important that we understand it to give us the best chance of fighting the disease. For example, if we do find that the way the innate immune system works plays a role, we can advise people on ways to improve that system, such as through what we eat.

But that wont change the fact that the generally worse health among BAME groups in western societies is strongly linked to socioeconomic factors that are known to play a very significant role in this pandemic.

Read more:
Coronavirus: BAME deaths urgently need to be understood, including any potential genetic component - The Conversation UK

Recommendation and review posted by Bethany Smith

Good science fiction has always been based in truth. George Lucas borrowed from the history of World War II for the look and feel of the original Star Wars trilogy, even Mary Shellys Frankenstein, the first of the genre,* is steeped in allegory for the world she lived in.

But what about the accuracy of the science used in sci-fi? Some movies use a lot of suspension of disbelief, bad physics and downright poor research to propel their storyline forward.

While bad science in science fiction isnt necessarily bad to watch, here are some movies that get a lot right and some that really miss the mark.

These are not documentaries and should not be treated as such. They are Hollywoodized for the sake of audience attention spans and to make things more interesting.

(*Some cite Lady Margaret Cavendish as the spark for science fiction as a genre with her 1666 novel The Blazing World. Bottom line, the genre was pretty much invented by women, the gender most widely underrepresented throughout the genre, but thats another list.)

The Best

Keir Dullea in a scene from 2001: A Space Odyessy (1968).

2001: A Space Odyssey (1968) What is this movie about? A lot of things, and apparently according to director/writer Stanley Kubrick and co-writer Arthur C. Clarke, if you can figure it all out, they failed to do their jobs. Suffice it to say, the classic sci-fi movie is full of not only well-predicted events and ideas of the future (corporate sponsorship, commercial spaceflight) but it also did a remarkable job of staying as scientifically accurate as it could. Kubrick hired aerospace engineers to design devices in the spacecraft interiors instead of usual prop makers, and artists employed by NASA were hired to design spacesuits and capsules. The result was at first not well-received by audiences or critics but with time it found its place and cemented itself as one of the greatest and most accurate (scientifically speaking) films ever made. Rent it on Amazon Prime, Google Play, iTunes, Vudu and YouTube.

Jodie Foster stars in "Contact" (1997).

Contact (1997) While a lot of sci-fi nerds have a lot of issues with this one mostly due to the ending, which I personally enjoyed Contact has a lot of things going for it. First and foremost, it has a female main character! She is clearly the smartest person in the room, though the dudes around her arent as interested in listening to her. The story follows Dr. Ellie Arroway (Jodie Foster) and her work with the Search for Extraterrestrial Intelligence (SETI) program and her discovery of a radio transmission coming from around the Vega system, which relies on a series of prime numbers to send information from beyond our solar system. The novel the film is based on took an unusual route to existence. Author and scientist Carl Sagan and Ann Druyan worked together to create a screenplay in 1979. When the original film stalled, Sagan turned it into a book, which was then made into the film after his death. The movie that was made follows Sagans original story well along with the science and protocols that exist in real life. Rent it on Amazon Prime, Google Play, iTunes, Vudu and YouTube.

Ethan Hawke in a scene from Gattaca (1997).

Gattaca (1997) The film starring Ethan Hawke, Jude Law and Uma Thurman is a staple in many science classrooms when discussing the subject of genetics. Following the idea that in the near future, parents can choose the genetic makeup of their children, making them more attractive, intelligent, faster, stronger, etc., it becomes more common for children to be conceived this way rather than the old-fashioned route. For the few who are conceived through traditional means, they are looked on as second-class citizens, struggling with diseases or other ailments that would never occur in humans whose genetics have been chosen for them. The movie sparks a great debate between science and nature, and prejudices based on DNA. Stream it on Crackle, Tubi or CBS All Access or rent it from Amazon Prime, Google Play, Vudu or YouTube.

A scene from "Finding Nemo" (2003).

Finding Nemo (2003) Yes, it may be surprising to see the heart-tugging animated movie about a fish is one of the more accurate films, but here it is. Ignoring the truth about real clownfishs ability to switch between using their male or female reproductive traits based on whether the dominant female in the community should die, the rest of the film depicts an unusually high accuracy when it comes to most marine biology and ecology. Fish do travel along the East Australian Current as described in the movie (though not as fast), and clownfish do live in sea anemones (at least the species depicted does), then there are the more subtle accuracies like the rows of sharks teeth, fish communications, even nods to poaching. The heartwarming story surrounds the incredible journey of clownfish Marlin and his search for his son Nemo, who has been scooped up by a diver and taken to Sydney. With the help of a forgetful blue tang fish named Dory, theyll go on the adventure of their lives to find Nemo. Stream it on Disney Plus or rent it from Amazon Prime, Google Play, iTunes, Vudu and YouTube.

Matt Damon stars in "The Martian" (2015).

The Martian (2015) The inciting incident of the film, a major storm that leaves scientist Mark Watney (played by the always steady Matt Damon) behind on Mars, isnt actually possible in real life, and there are a few liberties taken for the sake of drama and aesthetics. But a lot of films use of science is sound. Screenwriter and original novelist Andy Weir took great care to research the ins and outs of orbital mechanics, Martian conditions, spaceflight and botany. The film is a basic survival/rescue story that is well told and compelling throughout as NASA and the Chinese space program work together (what a concept!) to bring the lost astronaut home. Plus there are some great lines including Whatneys Im going to science the s--t outta this. Stream it on Hulu (with Live TV subscription) or rent it from Amazon Prime, Google Play, iTunes, Vudu or YouTube.

The Worst

Ben Affleck and Michael Clarke Duncan in a scene from "Armageddon" (1998).

Armageddon (1998) If you split an asteroid or giant meteorite in two, you will just have two of them to hit the earth. They wont conveniently split and go around it. Its also not a great movie.

Dennis Quaid, left, and Dash Mihok in "The Day After Tomorrow" (2004)

The Day After Tomorrow (2004) Arguably one of the most inaccurate depiction of the laws of thermodynamics and just a bad movie in general, The Day After Tomorrow ignores so many facts for the sake of drama its hard to list them all here. One of the main points is that the great freeze and sudden glaciation of the planet comes from a discovery on the part of paleoclimatologist Jack Hall (Dennis Quaid) that the Atlantic meridional overturning circulation current, which brings warm air from the equatorial tropics, has failed and this will cause another ice age. While the current is now known to be slowing down, and the climate of Western Europe will be drastically affected by it, its going to take around 400 years for that to happen. What follows in the film is even more egregious: Giant and impossible storms across the planet aid in triggering the ice age, ice sheets in Greenland melt suddenly and ocean levels rise at a laughable level. Then when the ice does form, the oceans dont then recede as normal physics dictates.

Sandra Bullock in a scene from Gravity (2013).

Gravity (2013) Between implausible events and just poor research, Gravity sinks into the worst category in terms of how it uses the science its trying to depict. For one, George Clooney is meant to be playing an incredibly adept astronaut, but the way he is portrayed as a braggart who showboats and takes a series of unnecessary risks while out on spacewalks. But the biggest problem comes with a spoiler and how space works. Youve been warned. George Clooney didnt have to die. Not even close to it. When he and Sandra Bullock are tethered, he decides to sacrifice himself and let go, floating off into the abyss. Well, thats not how space works. You cant just let go of something and expect to be flung off into oblivion without being pushed by something. Plus all that Sandra Bullock needed to do was give the rope a slight tug and good ol George would come sailing back up to her.

Sam Neill in a scene from Jurassic Park (1993)

Jurassic Park (1993) I will forever love this film no matter what. Its great and it holds up story-wise and effects-wise. Im not getting into its physical interpretations of some of the dinosaurs within it as it used the information they had available to them at the time. Heres the main thing the movie got wrong though: You really cant get the blood from a fossilized mosquito to give you the DNA patterns needed to replicate a dinosaur. The DNA would be destroyed after about 6 million years, and since the dinos they re-created lived something between 100-200 million years ago, it seems impossible to clone the creatures.

Scarlett Johansson in "Lucy" (2014).

Lucy (2013) The entire premise is based on the old saying that humans only use about 10 percent of their brain capacity and what would happen if someone could access 100% of that power. Well, its wrong from the get-go. Humans use 100% of their brain. Apparently, writer-director Luc Besson knew this and went for it anyway. That didnt make any difference the movie is still a stinker.

See original here:
Movies that got science right and ones that got it oh so wrong - Bend Bulletin

Recommendation and review posted by Bethany Smith

Dublin, May 22, 2020 (GLOBE NEWSWIRE) -- The "Fertility Clinics & Infertility Services Industry (U.S.)" report has been added to ResearchAndMarkets.com's offering.

This 4th edition report examines the $6 billion infertility services/fertility clinics industry.

This loosely regulated baby business grew strongly from 2014 to 2019, boosted both by demand domestically and via medical tourism patients from Europe and China. However, due to the Coronavirus, the industry will be hit hard in 2020, as many clinics shut down for two months and foreign patients are not coming to the U.S. any longer.

ART (assisted reproductive technology) now produces more than 50,000 babies per year in the U.S. via 330,000 IVF procedures, and demand is growing from the ranks of 7+ million infertile women, many of which delayed childbearing due to careers. There are about 450 U.S. fertility clinics, 100+ sperm banks, an unknown number of egg donors, and 1,700 reproductive endocrinologists competing for the business, which is lucrative.In addition, the U.S. market for fertility drugs is worth about $749 million. Only two large chains, IntegraMed and Prelude Fertility exist, as most programs are run by small MD practices or are part of a hospital or University. The market is fragmented, served by mostly small regional clinics.

This 4th edition study examines the nature/evolution of the business, national receipts/growth from 1988 to 2019, 2020 forecast, 2025 forecast, infertile customer demographics, key industry trends, industry regulation, pricing, industry consolidation, insurance coverage, ethical issues, and more. Contains results of the latest (2015-2018) CDC ART survey national data, with IVF success rates and long-term trends, as well as European ART cycles and outlook. The report also examines the nature/size of the U.S. sperm banks, egg donors, and fertility drugs markets, and surrogacy programs.

Key Topics Covered:

1. Introduction

2. Report Scope & Methodology, Sources used

3. Executive Overview of Major Findings

4. Nature & Structure of the Industry

5. Patient Demographics

6. Industry Size and Growth

7. Sperm Banks

8. Egg Donor Market

9. The Fertility Drugs Market

10. Findings of 2016-2018 CDC ART Surveys on Assisted Reproductive Technology

11. Tables and analyses of 2016 report: National Summary

12. Text, analyses & discussion covering these topics: (long-term trend data)

13. List of recent fertility start-up companies.

14. Industry Reference Directory

15. List of adoption and fertility services industry trade groups, associations, surveys, consultants, articles, and other sources.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/y55htc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More here:
Insights into the Fertility Clinics & Infertility Services Industry in the US to 2025 - Featuring Allan Guttmacher Institute, California Cryobank...

Recommendation and review posted by Bethany Smith

22 May 2020

Hair thinning is when one experiences mild to moderate hair loss for an extended period of time. Your hair loses its volume and gives the appearance of thinner areas of hair on your head.

Hair thinning

This is a concern for most people and many companies such asManual, a UK company offer treatments to combat this.

A lot of factors contribute to hair loss. Medical conditions, genetics, and the aging process have been highlighted many times in the past. However, not many are aware that your diet can play a big part in it too.

In this article, well take a look at how the lack of (or excess) nutrients may be linked with hair thinning.

What is a Nutrient Deficiency?

Nutrient deficiency or malnutrition is when your body does not get enough vitamins or minerals needed to sustain itself. You may picture this happening in only the poverty-ridden places in the world, but dont be surprised that your traditional Western dietcan lack certain nutrients as well.

Now, lets take a look at the nutrients commonly linked to hair loss:

Iron

Iron deficiency is the most common type of nutrient deficiency. Foods rich in iron include beef, chicken liver, and sardines. Contrary to popular belief, vegans and vegetarians arent at a higher risk of iron deficiency if their diets are well-balanced with a reasonable portion of whole grains, legumes, and nuts.

Women of reproductive age are more susceptible to iron deficiency due to excessive blood loss during their menstrual cycles.

Iron is crucial in the process of cell growth. They are a component of an enzyme called ribonucleotide reductase. When iron levels are low, hair follicles may not be able to grow effectively, and the amount of hair you naturally shed every day outpaces the rate in which your hair grows.

Vitamin A

Vitamin A can be found naturally in many of our food sources such as leafy vegetables, eggs, and fish. This vitamin is important in cell growth. Generally speaking, if you follow a Western diet, the risk of vitamin A deficiency is unlikely.

Based on current research, there isnt solid evidence to state that vitamin A deficiency can cause hair thinning. However, high levels of vitamin A can.

According to hairlossdoctors.com, excessive vitamin A causes hair follicles to reach the end of the growth phase quicker and fall off faster than the rate in which the body produces more hair.

Vitamin D

The sunshine vitamin or vitamin D is unique in the sense that it acts similarly to hormones. Currently, research has shown a link between vitamin D deficiency and alopecia areata, a disorder that causes bald patches to form.

Vitamin D encourages hair follicle growth and your hair growth may be negatively affected when you dont have enough of it. A natural way to get your daily dose of vitamin D is to be out and about under the sun for 10-30 minutes multiple days a week followed by a diet consisting, fatty fish, egg yolks, mushrooms, and cheese.

During the colder months where there isnt much daylight, you should consider supplementing yourself with vitamin D, as suggested by the NHS.

Disclaimer

Although there are links between nutrient deficiencies and hair loss, there isnt a lot of evidence that could directly correlate this to hair loss and the advice here should not be taken as medical advice. If you are experiencing thinning hair, you should consult your dermatologist as they will assess their patients on a case-by-case basis.

More here:
Nutrition and Hair Thinning - FemaleFirst.co.uk

Recommendation and review posted by Bethany Smith

We dont know if the intention of the creators of Twitter was the platform to become a place for ongoing discussion of any topics; what seems increasingly evident is that it is the social network of the opinadores. And with their tweets as a speaker, some people become trend by launching their reflections more or less successful.

One of the last to become viral has been Wall Street Wolverinean influencer remarkable with close to 100,000 followers he says that to say that the beauty standards are more stringent in women that in men is have no idea. A little bit of the urge to fight had, it is hard to see another way.

Wolverine is also youtuberwith 300,000 followers on that platform talking about political and economical topics. But yesterday he stressed especially on Twitter for his attempts to prove that being attractive is more difficult for men than for women. And first example, puts Margot Robbie at the side of Chris Hemsworth, perhaps a comparison is ill-chosen.

His meditations include phrases like this: A woman with a balanced diet and exercise you can achieve that physique without too much of a problem with constancy. The physical man are, instead, very advanced. Are physical or many years of training or directly use chemistry to achieve it. Given the fact that in order to be attractive you have to be a weightlifter semi-professional, of course.

Among the thousands of comments, a high percentage despising the words of Wolverine, there is a multitude of girls that argue that even doing exercise and maintaining a healthy diet will not get those bodies Something obvious to anyone familiar with the concepts of metabolism and genetics, but the youtuber refuses to accept as well.

Nor is it easy to follow him in his thread of reasoning: it Is a glimpse of a culture of envy and mediocrity tremendous. Chasing the extraordinary vanagloriar conformismshe says as an apparent response to the criticism he has been receiving and as a meditation end of the thread. Ehm, what?

The fact that put to Angelina Jolie as one of the female examples, suspect that has happened at some time or other the operating room, gives a clue that the argument has, to be generous, points flimsy. As his own formulation to begin with.

Read more:
Is it more difficult to be good that be good? The debate is on Twitter - Play Crazy Game

Recommendation and review posted by Bethany Smith

Welcome back to The Rundown, our daily breakdown on comic news stories we missed from the previous day. Have a link to share? Email our team at rundown@multiversitycomics.com.

In case you missed it, we got an exclusive preview of Sera and the Royal Stars #7.

Nathan W. Pyles Strange Planet will be getting a subscription box from Culturefly, The Pop Insider reports. Fans will be able to get exclusive merchandise inspired by the comic as part of this new subscription box. Each box includes a vinyl figure, an exclusive comic on a canvas print, and five to seven additional items featuring the creatures. The subscription box will launch on June 1.

Via Bleeding Cool, Doctor Who fans were treated to a special comic strip written by James Peaty, illustrated by Mike Collins, and narrated by Richard Ashton, in which fans find out more about Danny Pink. Its unclear when the next series of Doctor Who will premiere, although the show will return in the next year with the special Revolution of the Daleks.

Variety reports that Nick Jonas and Lawrence Fishburne are set to star in AGC Studios The Blacksmith, based on the graphic novel from Kickstart Comics by Malik Evans and Richard Sparkman. Pierre Morel (Taken) will direct from a screenplay adapted by Ben Ripley (Flatliners). Jonas will play Wes Loomis, a go-to weapons expert for the intelligence community, who goes on the run after his lab is destroyed and colleagues are murdered. Fishburne will play Mather, a retired blacksmith, and Loomiss mentor. With the aid of a CIA analyst named Noelle Hazlitt, the trio will embark on a journey that keeps this improbable pair one step ahead of their pursuers in a breathless, action-filled thriller. Production on the film will begin later in 2020.

Via Comicbook.com, Cartoon Network announced that We Bare Bears: The Movie will officially release for purchase on digital platforms on June 8, 2020. This is the first movie for the We Bare Bears franchise, which follows three talking bears as they explore life in the woods and city. In addition to the release date, Cartoon Network has also revealed a poster and trailer. The movie will depict the bears as they make their way to Canada after being chased from their home by antagonist, Agent Trout. Eric Edelstein, Demetri Martin, and Bobby Moynihan star in the movie as the bears Grizz, Ice, and Panda. Agent Trout is voiced by Marc Evan Jackson and many of the shows guest stars will also be featured in the movie. We Bare Bears: The Movie is scheduled to release for purchase on digital platforms for $14.99 on June 8, 2020.

Netflix has released the official trailer for The Old Guard, based on the comic by Greg Rucka and Leandro Fernandez. Like the comic, the movie follows a group of immortal soldiers led by Andy, played by Charlize Theron, who must fight to keep their immortality a secret, or otherwise see their gifts exploited. The film will begin streaming on Netflix on July 10, 2020. You can check out the trailer here.

Deadline reports that Sony has hired Marc Guggenheim to write a script for Jackpot, another installment in the larger Spider-Man Cinematic universe following the Venom franchise, and Jared Letos Morbius. In the comics, Jackpot is Sara Ehret, a scientist, who, while pregnant, is doing gene therapy research and is exposed to Lot 777, a virus that rewrites the DNA in her cells. She becomes imbued with superhuman strength and takes on the name Jackpot. Morbius is scheduled to be released on March 19, 2021, while Venom: Let There Be Carnage is set to hit theaters June 25, 2021.

TV Line reports that ABC has renewed 13 shows on their current lineup, including Stumptown. The TV show is based on the comic book series from creators Greg Rucka and Matthew Southworth, and follows Dex, an army vet turned private detective. Season 1 premiered in September. Its unknown when production will begin on season 2 of Stumptown.

Here is the original post:
The Rundown: May 22, 2020 - Multiversity Comics

Recommendation and review posted by Bethany Smith

The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.

BY Dr. Ian Flinn

The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.

In an interview with CURE, Flinn, the director of lymphoma research at Sarah Cannon Research Institute, discussed the use of CAR T-cells to treat lymphomas, as well as how the ZUMA-2 trial is shaping up to influence the treatment of patients with mantle cell lymphoma.

Transcription:

CURE: I'm curious about the ZUMA-2 trial. I know that you're an investigator on that trial. So, if you could talk a little bit about the drug, what it targets, how it works in the body and where things are with that study so far.

Flinn: ZUMA-2 is a clinical trial looking at a CAR T-cell product that targets CD19, which is an antigen on a lot of lymphomas, in this case mantle cell lymphoma, in patients who have had multiple prior therapies for their mantle cell lymphoma, and who are really no longer responding.

So, in this trial, we administered CAR T-cells to these patients. And after giving them some what's called lymphodepleting chemotherapy, and then infuse the CAR T-cells into the patients, we saw a really pretty remarkable outcome.

First (let me offer) a little bit about what a CAR T-cell is. Its a white blood cell, a lymphocyte, that is harvested from the blood of a patient. It's then sent to a central manufacturing facility, where a gene is inserted into the lymphocyte to have the lymphocyte activate as well as target the lymphoma. In this case, it's targeting that antigen called CD19, that's present on most B cell lymphomas and most all the mantle cell lymphoma, many other types of lymphoma as well.

So, it's a really exciting development in the treatment of all lymphomas and in certain forms of leukemia. A similar CAR T-cell product had previously been shown to be very effective in patients with an aggressive form of lymphoma, known as large cell lymphoma. And studies in that patient population led to the approval of CAR T-cells for patients with diffuse large B-cell lymphoma, who also similarly were not really responding to any agents anymore. The therapy had really run the course of what conventional treatments (could offer). And in that patient population there was about a 40%, what looks like long term cure rate for that patient population, so really fabulous results in large cell lymphoma.

And so, in this trial, this trial ZUMA-2, we're hoping to see similar activity in patients with, again, very difficult-to-treat mantle cell lymphoma, patients who already had standard of care therapies such as a tyrosine kinase inhibitor, and chemo immunotherapy. And we saw very remarkable results. Two-thirds of patients achieved a complete remission in this study, and the follow up is relatively short, but in a subgroup of patients that have been followed for more than two years on, about 40% of patients remain in remission.

So, this would be the first CAR T-cell product that will be available to patients with mantle cell lymphoma?

Right. This would be the first CAR T-cell product that's available for mantle cell lymphoma patients. We hope to see FDA approval sometime this summer. It's been submitted to the FDA for approval, and they have certain timelines that the FDA has to make. And based on that, we know that we should hear the latest by August on whether this drug will be approved.

Is there anything else that people should know about this particular study?

I think the other thing to know is when anybody is looking at any kind of therapy, is what are the risks and benefits of this? It sounds wonderful, augmenting the immune system and you're harnessing the immune system to fight the cancer, which is really what this is doing. But it does have side effects. And, and those side effects are sometimes scary.

There's something called cytokine release syndrome, where basically as I explain it to patients, it's like someone's getting the worst flu of their life. I mean, sometimes they can have fevers as high as 104 (degrees). But when you think about it, that's kind of what we're wanting. We want the immune system to be turned on. We want it to go after this lymphoma, what it thinks is foreign. (But) then we've learned better ways of decreasing those side effects now by using other medications to decrease the incidence and severity of cytokine release syndrome.

The other toxicity is called neurological toxicity, or neurotoxicity, and this can be very disturbing to patients and their family members. Because it can sometimes range from just being a little bit sleepy to people being in a full coma. Luckily, nobody died in this study from this, and we're getting better at intervening earlier to decrease the severity of neurologic toxicity. And so, for the vast majority of patients, it's reversible, but it's definitely something for patients who are considering this (drug) to talk to their doctor about.

Read more here:
CAR T-Cell Therapy a 'Really Exciting' Development in Treatment of Lymphomas - Curetoday.com

Recommendation and review posted by Bethany Smith

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Direct-to-Consumer Genetic Testing market.

Trusted Business Insights presents an updated and Latest Study on Direct-to-Consumer Genetic Testing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Direct-to-Consumer Genetic Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Direct-to-Consumer Genetic Testing MarketIndustry / Sector Trends

Direct-to-Consumer Genetic Testing Market size was valued at USD 831.5 million in 2018 and is expected to witness 15.2% CAGR from 2019 to 2025.

U.S. DTC Genetic Testing Market Size, By Test Type, 2018 & 2025 (USD Million)

Rising prevalence of genetic diseases such as cystic fibrosis and Alzheimers globally is one of the major factors fostering direct-to-consumer genetic testing market growth. According to Global Genes, over 300 million people globally suffer from rare diseases. Recently developed DTC genetic tests allows consumer to identify probability of acquiring a specific genetic disease. Therefore, increasing adoption of DTC genetic testing for early disease detection and identification of genetic diseases will boost the industry growth over forecast timeline.

Increasing demand for personalized medications to treat genetic diseases will positively impact industry growth in forthcoming years. Individuals genome must be tested to develop personalized medicines. This increases the demand for DTC genetic kits since, it provides detailed information about individuals genetic predisposition. As detailed information regarding genetic makeup of individuals is easily available with the use of DTC genetic kits, researchers can easily design and develop personalized medicine that would help in faster patient recovery. Aforementioned factor is expected to drive the industry growth. However, high cost of DTC genetic testing kits may hamper industry growth to some extent during the forecast period.

Market Segmentation, Outlook & Regional Insights: Direct-to-Consumer Genetic Testing Market

Direct-to-Consumer Genetic Testing Market, By Test Type

Predictive testing segment will experience around 17% growth throughout the analysis period. Considerable segmental growth can be associated with rising prevalence of genetic diseases. Recently developed DTC genetic tests help to identify mutations that increase the chances of acquiring specific disease accurately. Surging awareness regarding benefits of such presymptomatic testing has reduced the mortality rates by enabling effective management of disease. Above mentioned factors have stimulated the segmental growth that is predicted to continue over the forecast timeframe.

Ancestry and relationship testing segment accounted for over 43% revenue share in 2018. Increasing awareness regarding ethnicity tests amongst the American and European population has increased the demand for DTC genetic tests. Accuracy and efficiency possessed by these tests has fostered segmental growth. Moreover, ancestry tests developed by companies such as Ancestry.com are user friendly. Availability of robust DTC ancestry tests providing meaningful clinical, genealogical and even forensic information will positively impact the segment growth.

Direct-to-Consumer Genetic Testing Market, By Technology

Targeted analysis segment was valued over USD 310 million in 2018. Targeted analysis is utilized for determining the defects in genes that are responsible for a particular disorder. Targeted genotyping can accurately measure an individuals gene pool that encodes important information regarding various diseases. Targeted analysis can be conducted at significant low cost compared to other available techniques that should augment its adoption rate over forecast timeframe.

Single nucleotide polymorphism segment will experience around 15% growth throughout the forecast period. Single nucleotide polymorphism chips specifically detect changes in single nucleotide that increases the efficiency of tests. For instance, SNP chips utilized for diagnosing hereditary cancers have detected 1300 mutations in BRCA2 genes. Various companies such as Ancestry.com and Color Genomics utilize SNP arrays that analyse gene sequences at a specific resolution and reveal detailed analysis about the defective genes that may in future cause certain disease. Increasing adoption of such advanced SNP chips in DTC testing kits will trigger the segmental growth.

Germany DTC Genetic Testing Market Size, By Technology, 2018 (USD Million)

Direct-to-Consumer Genetic Testing Market, By Region

North America direct-to-consumer genetic testing market accounted for around 39% regional share in 2018. Regional market growth can be attributed to increasing prevalence of genetic diseases. Rare genetic diseases such as thalassemia, hemophilia and anaemia require continuous and critical monitoring. According to CDC, every year more than 1,000 people are affected by thalassemia. Furthermore, American population has higher literacy rate and also, awareness regarding DTC tests is high amongst the American population that augments demand for DTC genetic tests.

Europe is estimated to experience around 15% growth over the coming years. European direct-to-consumer genetic testing market is highly regulated and for carrying out some of the genetic tests through DTC kits, customers are required to have physicians prescription. However, currently, European regulatory bodies are working on improving regulations set on DTC tests due to improved accuracy and efficiency possessed by them. Thus, improvement in regulatory scenario will positively impact regional market growth.

Latin America DTC Genetic Testing Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Direct-to-Consumer Genetic Testing Market

Few of the eminent industry players operating in direct-to-consumer genetic testing market are Ancestry, 23andMe, Color, Family Tree DNA, EasyDNA, Helix, Identigene, Full Genomes, Genesis HealthCare, Karmagenes, MyHeritage, MapMyGenome, Living DNA and Pathway Genomics. Chief industry players implement numerous initiatives such as mergers, acquisitions and new product launch to maintain their market position. Receiving approvals from regulatory bodies for new products will also foster companys revenue share. For instance, in October 2018, 23andme received first U.S. FDA approval for de novotechnology utilized in pharmacogenomic tests. This approval will enable company to launch innovative products, thereby fostering companys growth.

Direct-to-Consumer (DTC) Genetic Testing Industry Viewpoint

Direct-to-consumer genetic testing industry can be traced back to early 2000s. Earlier DTC tests were thought to be convenient as they would allow the patients to access their genetic information without involvement of physician. Although, DTC genetic testing kits had several benefits, in the initial days, they were stringently regulated by regulatory bodies. Regulatory scenario has always been stringent since the introduction of DTC genetic kits in European countries. Currently, there has been change in the regulatory scenario and European countries have started receiving approval for DTC genetic kits. Defects in the DTC kits have been reduced and people have started relying on these kits. DTC genetic testing market is sort of matured in North America due to numerous technological advancements and is still in developing phase in Asian countries. With further advancements in technology, DTC genetic tests industry will experience numerous growth opportunitie

Key Insights Covered: Exhaustive Direct-to-Consumer Genetic Testing Market1. Market size (sales, revenue and growth rate) of Direct-to-Consumer Genetic Testing industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Direct-to-Consumer Genetic Testing industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Direct-to-Consumer Genetic Testing industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Direct-to-Consumer Genetic Testing industry.

Research Methodology: Direct-to-Consumer Genetic Testing Market

Quick Read Table of Contents of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the rest here:
Direct-to-Consumer Genetic Testing Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Cole of Duty

Recommendation and review posted by Bethany Smith

Direct-To-Consumer Genetic Testing Market 2020 report share informative data figures as well as important insights regarding some of the market component which is considered to be future course architects for the market. This includes factors such as market size, market share, market segmentation, significant growth drivers, market competition, different aspects impacting economic cycles in the market, demand, expected business up-downs, changing customer sentiments, key companies operating in the Direct-To-Consumer Genetic Testing Market, etc. In order to deliver a complete understanding of the global market, the report also shares some of the useful details regarding regional as well as significant domestic markets. The report presents a 360-degree overview and SWOT analysis of the competitive landscape of the industries.

Top Key players of Direct-To-Consumer Genetic Testing Market Covered In The Report:AncestryColorEasyDNAFamily Tree DNAFull GenomesGenesis HealthCareHelixIdentigeneKarmagenesLiving DNAMapMyGenome. Key Market Segmentation of Direct-To-Consumer Genetic Testing:

Market by Test Type

(Ancestry & Relationship Testing, Carrier Testing, Predictive Testing, and Nutrigenomics Testing)

Technology

(Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, and Whole Genome Sequencing (WGS))

Direct-To-Consumer Genetic Testing Market Region Mainly Focusing:

Europe Direct-To-Consumer Genetic Testing Market (Austria, France, Finland, Switzerland, Italy, Germany, Netherlands, Poland, Russia, Spain, Sweden, Turkey, UK), Asia-Pacific and Australia Direct-To-Consumer Genetic Testing Market (China, South Korea, Thailand, India, Vietnam, Malaysia, Indonesia, and Japan), The Middle East and Africa Direct-To-Consumer Genetic Testing Market (Saudi Arabia, South Africa, Egypt, Morocco, and Nigeria), Latin America/South America Direct-To-Consumer Genetic Testing Market (Brazil and Argentina), North America Direct-To-Consumer Genetic Testing Market (Canada, Mexico, and The USA)

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

Buy Full Report Now @ https://www.qurateresearch.com/report/buy/HnM/direct-to-consumer-genetic-testing-market/QBI-CMR-HnM-738584/

(A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.)

Key Highlights from Direct-To-Consumer Genetic Testing Market Study:

Income and Sales Estimation Historical Revenue and deals volume is displayed and supports information is triangulated with best down and base up ways to deal with figure finish market measure and to estimate conjecture numbers for key areas shrouded in the Direct-To-Consumer Genetic Testing report alongside arranged and very much perceived Types and end-utilize industry. Moreover, macroeconomic factor and administrative procedures are discovered explanation in Direct-To-Consumer Genetic Testing industry advancement and perceptive examination.

Assembling Analysis The Direct-To-Consumer Genetic Testing report is presently broke down concerning different types and applications. The Direct-To-Consumer Genetic Testing market gives a section featuring the assembling procedure examination approved by means of essential data gathered through Industry specialists and Key authorities of profiled organizations.

Competition Analysis Direct-To-Consumer Genetic Testing Leading players have been considered relying upon their organization profile, item portfolio, limit, item/benefit value, deals, and cost/benefit.

Demand and Supply and Effectiveness Direct-To-Consumer Genetic Testing report moreover gives support, Production, Consumption and (Export and Import).

Major Points Covered in Table of Contents:

Direct-To-Consumer Genetic Testing Market OverviewMarket Competition by ManufacturersProduction Market Share by RegionsConsumption by RegionsGlobal Direct-To-Consumer Genetic Testing Production, Revenue, Price Trend by TypeGlobal Direct-To-Consumer Genetic Testing Market Analysis by ApplicationsCompany Profiles and Key Figures in Direct-To-Consumer Genetic Testing BusinessDirect-To-Consumer Genetic Testing Manufacturing Cost AnalysisMarketing Channel, Distributors, and CustomersMarket DynamicsGlobal Direct-To-Consumer Genetic Testing Market ForecastResearch Findings and ConclusionMethodology and Data Source

In a word, the Direct-To-Consumer Genetic Testing Market report provides major statistics on the state of the Direct-To-Consumer Genetic Testing industry with a valuable source of guidance and direction for companies and individuals interested in the market. At the end, Direct-To-Consumer Genetic Testing Market Report delivers a conclusion which includes Research Findings, Market Size Evaluation, Global Market Share, Consumer Needs along with Customer Preference Change, Data Source. These factors will raise the growth of the business overall.

Contact Us:

Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221

Note: In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Read more:
Direct-To-Consumer Genetic Testing Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2027 - Cole of Duty

Recommendation and review posted by Bethany Smith

The global Direct-To-Consumer (DTC) Genetic Testing market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Direct-To-Consumer (DTC) Genetic Testing market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Direct-To-Consumer (DTC) Genetic Testing market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Direct-To-Consumer (DTC) Genetic Testing market. The Direct-To-Consumer (DTC) Genetic Testing market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2637644&source=atm

The key players covered in this studyAncestryColor GenomicsEasy DNAFamilytreeDNA (Gene By Gene)Full Genome CorporationHelix OpCo LLCIdentigeneKarmagenesLiving DNAMapmygenomeMyHeritagePathway GenomicsGenesis Healthcare23andMe

Market segment by Type, the product can be split intoCarrier TestingPredictive TestingAncestry & Relationship TestingNutrigenomics TestingOthersMarket segment by Application, split intoOnline PlatformsOver-the-Counter

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Direct-To-Consumer (DTC) Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the Direct-To-Consumer (DTC) Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Direct-To-Consumer (DTC) Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2637644&source=atm

The Direct-To-Consumer (DTC) Genetic Testing market research covers an exhaustive analysis of the following data:

The Direct-To-Consumer (DTC) Genetic Testing market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2637644&licType=S&source=atm

The global Direct-To-Consumer (DTC) Genetic Testing market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Read the rest here:
COVID-19: Responding to the business impacts of Good Growth Opportunities in Global Direct-To-Consumer (DTC) Genetic Testing Market - Cole of Duty

Recommendation and review posted by Bethany Smith

Safety4Her was founded by Melissa Gaglione, who saw a need and opportunity for womens clothing in the towing and trucking industry.

With the trucking, towing and manufacturing industry employing more than 5 million women and a growth rate of 22 percent annually, she decided it was time for clothing that women in those industries would want to wear.

I started my company, because I was a woman in the towing and trucking industry and found that wherever I searched, there was nothing that fit me, Gaglione said. There are no small sizes and everything was made in one size.

The existing market for safety wear is mostly for men and does not provide materials or fits that most women would find comfortable. A poor fit can cause women to face a higher risk of injury or death think baggy clothing caught in machinery which can also increase insurance risks.

In 2017 alone, Gaglione said, there were 250,000 accidents due to ill-fitting safety wear. Gaglione said she knows of some companies that sell pink safety wear, but much of it doesnt comply with the American National Standards Institute, which establishes various safety standards.

She not only made her clothing compliant with ANSI, but comfortable. All her garments are inspired by typical yoga pants, as she got her start by simply sewing on reflective gear to her yoga pants and leggings. She eventually made her own designs for women of all sizes.

Read the full story at WisBusiness.com: https://www.wisbusiness.com/?p=1452259

This weeks episode of WisBusiness: The Podcast features Buckley Brinkman, executive director and CEO of the Wisconsin Center for Manufacturing and Productivity.

WCMP collaborates with the UW Stout Manufacturing Outreach Center and the Wisconsin Manufacturing Extension Partnership to help the states manufacturers grow their businesses and become more profitable by offering services and programs.

What were doing now is helping manufacturers start to figure out how theyre going to operate, safely, responsibly and effectively as we come out of this as a state and as a nation, Buckley said.

Brinkman will also be a panelist at the 2020 Wisconsin Entrepreneurs Conference put on by the Wisconsin Technology Council on June 4. The virtual event will focus on COVID-19 economic survival, recovery and prosperity for young companies during a new normal.

He is bringing his broad perspective and connections with manufacturers across the nation, with knowledge on how cutting edge technology is implemented in manufacturing operations.

Every time we come out of a downturn, the investment in technology actually speeds up rather than slows down, said Brinkman. The companies that are going to come out of this stronger are the ones that are already making plans and looking for new opportunities for their businesses to take advantage of as the economy recovers.

Brinkman is looking forward to coming away with two or three ideas to put to use as well as two or three things that push him to think harder about what hes doing.

I just think this is an exciting time for us, I think its going to be an opportunity for all of us to show what Wisconsin can do, both in terms of our ability to open responsibility but then also to take advantage of the new opportunities that are coming along in this new economy, he said.

Listen to the podcast, sponsored by UW-Madison: https://www.wisbusiness.com/?p=1452256

The states unemployment rate soared to 14.1 percent in April, reaching a level not seen since the Great Depression.

According to a release from the state Department of Workforce Development, Wisconsins unemployment rate in April was 0.6 percent lower than the national rate of 14.7 percent.

The massive increase comes after the state was experiencing near-record low unemployment rates, with 3.1 percent in early March. More than 385,000 private-sector jobs were lost over the course of a single month, according to DWD.

The economy has taken a pretty severe hit in a very rapid manner, said DWD Chief Economist Dennis Winters in a media briefing today.

He explained the states unemployment rate approached 10 percent in the Great Recession of 2008, just under the national rate at the time. Winters also said the state didnt see current levels in a previous recession in the early 1980s.

The closest is the Great Depression when they figured the unemployment rate was around 25 percent, he said, adding that the depression of the 1930s built up over the course of months and years. This is a totally different phenomenon.

In early April, DWD had projected the states unemployment rate could reach as high as 27 percent. But based on the most recent information, Winters said the odds of that are less than 50 percent at this point.

Since the unemployment statistics are delayed by several weeks, Winters said they likely wont reflect the impact of the stay-at-home order and business restrictions being lifted until early July.

After peaking in early April, the number of initial unemployment applications in Wisconsin has since leveled off, according to the DWD website. But the daily totals are still in the thousands, and much higher than the same time last year. Between March 15 and May 16, DWD received 549,147 initial unemployment applications.

Wisconsin Manufacturers & Commerce President & CEO Kurt Bauer said a prolonged shutdown due to COVID-19 would likely be a much greater threat to the state than the virus itself.

Now is the time to return to the policies that delivered the strongest economy, lowest unemployment and largest budget reserves in Wisconsin history, he said. Wisconsin must reduce taxes, cut job-strangling red tape, and enact liability reforms that protect employers from costly and frivolous lawsuits.

See the release:

http://dwd.wisconsin.gov/news/2020/unemployment/200521-april-state.pdf

See the latest unemployment application numbers:

http://dwd.wisconsin.gov/covid19/public/ui-stats.htm

See the WMC statement:

Gov. Tony Evers says the state will dedicate $100 million from the federal CARES Act to help long-term care providers, emergency medical services, and home and community-based services.

The money is the latest chunk of the federal funding that Evers has rolled out to help various industries impacted by COVID-19. Hes now announced plans for more than $1.4 billion of the nearly $1.9 billion sent to the state.

The $100 million will be doled out in two parts. The initial phase will support immediate needs with a second release the administration says will be more targeted to additional needs of providers. In both cases, the money will support expenses directly related to COVID-19 and unexpected costs such as overtime and changes to sanitation procedures.

On a call with reporters today, Evers said the state will use how much Medicaid funding applicants receive as a basis to help divvy up the $100 million.

Evers acknowledged needs outstrip the amount of money being made available, noting he had earlier called for state money to help the facilities. But Republican lawmakers rejected his legislation that included the money.

Certainly, we will look at it, Evers said of additional state funding. But we also want to use as many resources as possible from the federal government.

Earlier today, Assembly Minority Leader Jim Steineke, R-Kaukauha, chided Evers in a letter for not providing money to long-term care facilities.

Following the announcement, Steineke said the money was better than nothing. Steineke added he heard frustrations from those in the long-term care industry that they hadnt been consulted by Evers and said providing state money isnt an option because Wisconsin is fundamentally broke.

While its a significant amount of money, in the long run its going to fall well short of what the needs are, Steineke said.

See the release:

Read Steinekes letter:

https://www.wispolitics.com/wp-content/uploads/2020/05/200521Steineke.pdf

A professor in the UW-Madison Department of Pathology and Laboratory Medicine, David OConnor, is working to develop a COVID-19 test to be used in institutions such as nursing homes or large workplaces.

OConnor was a panelist in the Wisconsin Alumni and Research Foundations third COVID-19 edition of its event series Crossroads of Ideas titled Where do we go from here?

He is anticipating federal guidelines are going to change on patients needing to be symptomatic for a test, as his lab is aiming for this test to be used for pre-symptomatic people.

He is working with Profs. Dave Beebe and Tom Friedrich to develop a colorimetric test for the virus, SARS-CoV-2 that causes the disease, COVID-19. OConnor said that one of the testing limitations right now is that it needs to take place in centralized labs with fancy equipment. But in this rapid test, a swab sample that has the viruss nucleic acid or RNA would cause the material in a tube to turn yellow; if not, pink.

We imagine that a truly rapid test would need to be deployed to nursing homes, said OConnor, noting that there are 15,000 nursing homes in the nation. You can imagine having a device that can be deployed at nursing homes, at any nursing home that has ongoing cases, it could be, having their people tested every day.

Deployment of the test would depend on a pending grant with RADx, a government program thats designed to accelerate the development and deployment of tests like this, according to OConnor.

If it gets funded, RADx will do rapid development over about a four-week period to see if it would be feasible for commercialization on a scale of millions of tests per week. If so, they aim to have it available by the end of the summer highly ambitious, especially from where we are now, he said.

Looking ahead, OConnor doesnt know how COVID-19 will behave in the winter.

A lot of people who believe they were infected last winter, were infected with something else, possibly influenza B, possibly something else, he said adding that probably only 1 percent of people in Dane County had it last winter, and they would have been classified at a higher than average risk level.

With most people having not been infected, certainly around here, its going to be an open question what happens next winter.

Also in OConnors Laboratory, investigators lead CoVen, an international collaboration developing COVID-19 animal models to test vaccines and treatments. The group has also been responsible for sequencing SARS-CoV-2 genomes from cases throughout Dane and Milwaukee Counties to understand how these viruses are moving through Wisconsin.

Gentueri Inc. contributes 55,000 COVID-19 testing kits a week to the states lab capacity and is developing new testing kits that can be used in the workplace.

Gentueris main business is working with laboratories to improve result quality and lab efficiency by advancing collection, preservation and processing of biological samples with kits. They make sexual assault kits for the Wisconsin Crime Lab, collection kits and genetic testing kits.

In mid-March, after predicting a slowdown in business, Nagy decided to expand Gentueri from four employees to 25 and pivoted to produce COVID-19 testing kits that include the nasal swabs and Viral Transport Media material that keeps the virus alive in the sample for the lab for local laboratories.

We realized that there was a shortage of the kits out there, and the fact that were a biological sample collection company we figured we have the expertise to make these, said Randy Nagy, president and CEO of Gentueri.

After a call to the state hygiene laboratory, company officials sourced the materials they would need for the kits, purchased a machine to make the kits and started producing the kits. Theyve since expanded to help other states in need: Illinois, Missouri, Indiana, Nebraska, Michigan and Kansas.

According to Nagy, what employers are looking for now is a way to test their employees to make them feel safe. With expertise in sample collection, Gentueri is developing a CollectEject Swab Kit that uses an oral sample rather than the long thin swab taken high up in the nasal cavity.

This allows an individual to easily collect a sample themselves and send it to a lab for automated processing, said Nagy.

We see a big opportunity there and that will go until there is a vaccine available, he said. This pivot has given us exposure to the genetic testing world. We can help the community and the laboratories with their immediate problem. Were not only doing it ourselves, but helping other companies in the end to provide their services as well.

DHS is conducting 376 facility-wide investigations across the state, 77 more than last week.

Long-term care facilities account for 165 of them, followed closely by 148 non-health care workplace investigations.

Long-term care facilities in the state are reporting 205 deaths due to COVID-19, making up 42 percent of total deaths in Wisconsin due to the virus.

These include nursing homes and assisted living facilities, such as community-based residential facilities and residential care apartment complexes.

Thirty-two of the investigations are in group housing facilities including correctional facilities, homeless shelters, dormitories and group homes that have identified 21 COVID-19 deaths, or 4 percent of the states total.

One hundred and twenty-nine of the states COVID-19 deaths were not linked to group housing facilities, but 132 deaths are categorized as unknown, meaning they may or may not have occurred at these facilities.

According to DHS, the unknown category exists because relevant information has only been collected since April 8.

About 18 percent of confirmed COVID-19 patients who have died in the state were over 90 years old, while another 24 percent were between 80 and 89 years old. Another 28 percent were between 70 and 79, and 16 percent were between 60 and 69.

DHS is also conducting investigations in healthcare facilities (17) and other settings (14).

A majority of the investigations are taking place in Milwaukee (69) and Brown (60) counties.

Click here to see the facilities under investigation and a breakdown by county: https://www.dhs.wisconsin.gov/covid-19/investigations.htm

All 72 counties in Wisconsin have at least one confirmed case of COVID-19 after Langlade and Taylor counties had a case overnight.

DHS reports the states COVID-19 death toll at 487 up six from the last count.

The states number of confirmed cases also rose since the previous count by 472 bringing the cumulative case count to 13,885. The positive tests results account for 5 percent of the total tests received Thursday, which is a good percentage, DHS Secretary Andrea Palm said in a briefing.

An estimated 58 percent have recovered from COVID-19, while 4 percent of patients have died. Thirty-nine percent are still in a 30-day waiting period of symptom onset or diagnosis.

Counties reporting deaths include: Milwaukee (269), Brown (29), Dane (26), Waukesha (24), Kenosha (21), Racine (20), Rock (14), Ozaukee (11), Walworth (11), Grant (10), Outagamie (5), Clark (4), Fond du Lac (4), Richland (4) and Washington (4).

Door, Richland, Sauk and Sheboygan counties report three deaths each. Jefferson and Marinette counties report two deaths each.

Adams, Bayfield, Buffalo, Burnett, Calumet, Columbia, Dodge, Iron, Jackson, Juneau, Kewaunee, Manitowoc, Marathon, Marquette, Monroe, Polk, Waupaca and Winnebago counties report one death each.

Hospitalizations in the state are up.

Of the states 13,885 confirmed cases, 16 percent have been hospitalized and 4 percent have received intensive care, according to DHS.

And the Wisconsin Hospital Associations hospital dashboard reports 398 COVID patients in hospitals statewide, up five patients from Wednesday and 46 more than a week ago. WHAs statewide patient data shows an upward trend in hospitalized patients since May 6.

DHS Secretary Andrea Palm said its safe to say the uptick in hospitalizations right now is not a result of the end of the states stay-at-home order.

This is because hospitalization lag time is longer than the testing lag time and hospitalization isnt required until a patient has been infected for a while and symptoms get bad, usually three to five weeks post infection, according to Palm.

DHS reports that 292 of the total COVID patients are in southeastern Wisconsin, which has also seen an increase in hospitalizations since May 6.

It is why we have built and worked on this surge capacity, not only at the regional level with hospital systems across the state, but also through our alternative care facility in Milwaukee and the one that we have started here in Dane that we would be able stand up quickly if we needed to, Palm said.

The state is slowly moving up to reach its capacity of 14,140 tests per day after a total of 9,365 came back Thursday, the most of any day.

If youre experiencing any symptoms of COVID-19, please get a test, Palm said.

Click here for more coronavirus resources and updates: https://www.wispolitics.com/wisconsin-coronavirus-resources/

As White House officials reportedly pressure the CDC to raise the bar for how states count COVID-19 deaths, the state Department of Health Services says its only including cases that had a positive test and for which the virus caused the patient to die.

If they tested positive for COVID-19 by a confirmatory test (for example, a PCR test that detects the virus causing COVID-19, not an antibody test), and COVID-19 is listed among the primary causes of death or among contributing causes of death, they are counted as a COVID-19-associated death, said Elizabeth Goodsitt, a spokesperson for DHS.

According to a report from the Daily Beast, members of the presidents coronavirus task force have been seeking changes to the tallying process that would likely lead to fewer deaths being reported. The report cites five unnamed CDC officials and says President Trump has used hypotheticals in which someone who has the virus dies from an unrelated cause such as falling down the stairs, and is still counted as a COVID-19 death.

Other states are using varying methods to calculate the total death toll attributed to the virus, a report from the Washington Post shows. But in Wisconsin, health officials only count it as a COVID-19 death if the disease is listed among the primary causes of death or contributing causes of death.

Goodsitt said if health officials have reason to believe a death wasnt linked to COVID-19 at all, based on the assessment of a medical provider or medical examiner, then its not counted in the states tally of virus deaths.

For example, if a patient died from an overdose or a car accident, and they were not ill, or there was evidence that their illness did not contribute to their death, they are not counted as a COVID-19-associated death, even if COVID-19 is detected, Goodsitt said in an email.

See more in Top Stories below.

#TOP STORIES#

# Medical College CEO: Wisconsin has landmark day in testing Covid-19

Originally posted here:
FRI AM News: Safety4Her aims to provide the right clothing for women in the trades; WisBusiness: The Podcast features Buckley Brinkman, WCMP -...

Recommendation and review posted by Bethany Smith

THE world's top sports stars are preferring to use stem cell treatment, instead of undergoing major surgery that could leave them out for months.

Cristiano Ronaldo, Rafael Nadal, and most recently Mike Tyson have all tried the therapy, which can cost anywhere from 4,000 to 15,000, when they've suffered injury.

Ailments that can be treated, include tendon inflammation, muscle strain, arthritis, degenerative disc disease, and even bone fractures.

And sportsman who have undergone stem cell therapy are benefitting from improved results, as well as a faster recovery time.

Collected from the blood from a newborn babys umbilical cord, the bone marrow or from body fat, stem cells are injected into an athletes' affected area.

They get to work by replenishing damaged cells from an injury or through wear and tear.

Stem cells also help reduce pain and inflammation, increase blood flow, and promote soft-tissue growth.

It helps the body to heal naturally, and means sports stars can potentially avoid going under the surgeon's knife.

When you're a top sports star, if you get injured the first thing you want to do is get back into the thick of action as quick as possible.

Unfortunately, many injuries can take a long time to heal, and will never allow the sportsman in question to return to the same level he/she was at before the injury.

That's where stem cell treatment is a game-changer.

Forget surgery, steroid injections, and lengthy physiotherapy, which don't always repair the issue at hand.

Stem cell treatments offer an alternative, albeit at a price, to have a non-surgical therapy that's non-evasive and, more importantly, heals the problem fast cutting out the need of rehabilitation.

Better still, some patients have reported that the therapy has not only reversed existing damage, but has strengthened cells against further damage.

Juventus star Ronaldo and Spanish tennis hero Nadal are all fans of stem cell treatment.

Back in 2016, when the Portuguese forward was playing for Real Madrid, he suffered a hamstring tear that threatened to keep him out of action of an important Champions League game against Manchester City.

Although he missed the first leg, he was back for the second - less than three weeks after suffering the problem.

That same year, Ronaldo tore a collateral ligament in his knee during Portugals Euro 2016 final against France.

Again, he turned to stem cell treatment and was back in training with Los Blancos just a month after his knee complaint.

Nadal's chronic knee problems forced him to take seven months off from tennis in 2013.

But stem cell treatment allowed the cartilage to repair. In the seven years since he's won six Grand Slams, there's been no setbacks from his troublesome knee and he appears as mobile as ever.

The Spaniard also cured a long-standing back problem with the therapy.

The former heavyweight champion, who is considering making a comeback, is the latest name to have tried stem cell treatment.

EUR JOKINGCity, Chelsea & Man U's dreams in jeopardy as govt impose quarantine on arrivals

'ALWAYS SMILING'Ex-PSG ace Diakiese dies aged 24 as tributes paid for 'endearing boy'

Pictured

MIC DROPPEDLegendary WWE announcer Lilian Garcia shows off stunning beach body at 53

Pictured

ROSE TO FAMEWorld Series flasher Julia Rose posts outrageous snaps on Instagram

TIGER KINGWatch Mike Tyson spar and wrestle his 39st TIGER in shocking scenes

NET LOSSESTen stars who blew their football fortunes after reports Gyan has only 600

Pictured

A NEW PAIGEPaige VanZant's return set for July 11 on Fight Island vs Amanda Ribas

KEEP BEING YOURSELFMike Tyson tells Tyson Fury to 'stay the f*** away from normal'

It is not known what Tyson, 53, was suffering from - but he was happy to reveal all in an Instagram chat with basketball legend Shaquille O'Neal.

Iron Mike said: "You know what I had done? I had stem-cell research therapy.

"I feel like a different person but I can't comprehend why I feel this way. It's really wild what scientists can do."

See more here:
Tyson, Ronaldo, and more sports stars who use stem cell treatment costing up to 15,000 to speed up healing - The Sun

Recommendation and review posted by Bethany Smith

Before he knew Anuroop, Vihaan (right) addressed him as the Superhero.

Vihaan is a bright and active 4-year-old boy. He is a thalassemia survivor. And just over a year ago, he desperately needed a bone marrow transplant.

Anuroop, is a young man from Kerala. He doesn't know Vihaan's family. He just felt that donating bone marrow for someone in need was the right thing to do after he got a call from Datri, a non-profit agency coordinating such donations.

Anuroop told NDTV, "Actually, it was a matter of choice. I got a call from Datri about one year ago and they discussed with me this matter. They said, 'A 4 year old child, he is suffering from Thalassemia. Maybe only you can save him.' But at that point, I was not sure that I would do it. But later, with the support of my family and people from Datri, I decided to do it."

Anuroop and Vihaan came face to face - on camera - for the first time ever on NDTV. Anuroop was clearly emotional as he saw images of an active Vihaan, flanked by his parents, grinning and waving at the screen. Bhavana, Vihaan's mother was emotional too as she set eyes for the first time on Anuroop, who has given the family life and hope.

She told NDTV, "He is the answer to all our prayers. When Vihaan was diagnosed when he was 6 months old, we didn't know how Vihaan is going to be. We didn't know what to do. And then we went to Dr Sunil Bhatt and we registered with Datri. They told us that the procedure of finding a match is very difficult. And then we found a donor so we just couldn't believe that we were blessed to find a donor. Those were anxious days. But yeah, glad now."

Asked how her son was doing, Bhavana said, "Young Vihaan is doing great, thanks to Dr Sunil, thanks to Anuroop and thanks to God's grace. Vihaan is doing well."

Looking at the screen in front of her which showed, Anuroop, Dr Bhatta and Gayathri Shenoy of Datri, she told her son '"Just say hi, Vihaan!" He did, with a cheery wave.

Anuroop was moved by the response. He said, "I'm super excited - I waited for too long. I waited for one year. From that day of donation, the whole family, he was always in my prayers. I'm super excited now. That's all."

Finding a matching donor in a case like this is a very difficult task. Vihaan's doctor, Dr Sunil Bhatt, is HoD, Paediatric Haematology, Oncology, Bone Marrow Transplantation at the Mazumdar Shaw Cancer Centre in Bengaluru. And this professional medical man admitted to the deep emotions he feels at such times when a donor meets a recipient. "It gives me goosebumps," he told NDTV.

"You do so many times, again and again, but every time when an unrelated donor meets a patient - it is always an emotional moment for all of us," he said.

"Vihaan was diagnosed with a disease called Thalassemia at six months of age. What happens in this disease is that they don't make their own blood. So they have to be given blood transfusions from outside every few weeks to sustain life and that is life-long. But what blood does is it brings its own complications along with it and many of those and unfortunately most of these children do not live more than second or third decade of life. So the only cure for this is bone marrow transplantation and as we all know for Bone Marrow Transplantation we need someone to donate for them. There has to be a healthy donor who can donate," he said.

To find a matching donor is far from easy. Dr Bhatt said, "Sometimes you'll find that in the families - the chances of that being 25-30 per cent. But 70 per cent of the patients who require transplants will not have anyone in their families to donate for them. So here comes the role of unrelated donor transplantations that means someone else in the same country, in the world who matches the patient. And the chances of that being one in 20,000 to one in a million. So it depends on what ethnic background you're from - South Indian is going to match South Indian, North Indian going to match North Indian - chances will be higher in your own ethnic community. And hence the registries play a huge role because they enrol these unrelated healthy donors, put them on their database and when patients like Vihaan require such transplantation we approach these registries and ask them if there is any donor in the registry who is matching our patient. If there is one, that person is requested to donate and they donate stem cells to save someone's life."

Datri helped coordinate this life saving procedure with its all-important database. Gayathri Shenoy, Head-Patient Relations of Datri told NDTV, "I represent Datri which is India's largest blood stem cell registry. We are 10 years old and we have about 4.4 lakh registered donors and 712 donations of that. But as you can imagine that is a very small number compared to the population of our country because there are so many patients who have blood cancer who are waiting for their Anuroop to show up."

Asked if it had been physically difficult to donate bone marrow, Anuroop said, "Physically not that hard - like I need some rest but it is not that hard. Anyone can do it anytime if they find a match. I didn't find it very difficult and all. I heard some cases like people will be hesitant to do something like this - but I didn't find anything that should people hesitate. It is an easy process and you would be given a general anaesthesia. You won't be knowing anything."

Bhavana said, We just wanted to say that everyday in our prayers all of these people have been there. We didn't know the donor - so he was just addressed as the Superhero Donor, because it was very difficult to make Vihaan understand. Dr. Sunil, Datri - I don't know what we would have done if it was not for Datri. So just feeling blessed.

Original post:
When A Bone Marrow Donor Met His 4-Year-Old Recipient For The First Time - NDTV

Recommendation and review posted by Bethany Smith

Stem cell banking or preservation is a combined process of extraction, processing and storage of stem cells, so that they may be used for treatment of various medical conditions in the future, when required. Stem cells have the amazing power to get transformed into any tissue or organ in the body. In recent days, stem cells are used to treat variety of life-threatening diseases such as blood and bone marrow diseases, blood cancers, and immune disorders among others.

The market of stem cell banking is anticipated to grow with a significant rate in the coming years, owing to factors such as, development of novel technologies for stem cell preservation and processing, and storage; growing awareness on the potential of stem cells for various therapeutic conditions. Moreover, increasing investments in stem cell research is also expected to propel the growth of the stem cell banking market across the globe. On other hand rising burden of major diseases and emerging economies are expected to offer significant growth opportunities for the players operating in stem cell banking market.

Get Sample PDF Copy at https://www.theinsightpartners.com/sample/TIPBT00002082/

Market Segmentation:

The source segment includes, placental stem cells (PSCS), dental pulp-derived stem cells (DPSCS), bone marrow-derived stem cells (BMSCS), adipose tissue-derived stem cells (ADSCS), human embryo-derived stem cells (HESCS), and other stem cell sources. Based on service type the market is segmented into, sample processing, sample analysis, sample preservation and storage, sample collection and transportation. Based on application, the market is segmented as, clinical applications, research applications, and personalized banking applications.

Company Coverage:

1. Cordlife2. ViaCord (A Subsidiary of PerkinElmer)3. Cryo-Save AG4. StemCyte India Therapeutics Pvt. Ltd.5. Cryo-Cell International, Inc.6. SMART CELLS PLUS.7. Vita 348. LifeCell9. Global Cord Blood Corporation10. CBR Systems, Inc.

Avail Discount on Stem Cell Banking Market at https://www.theinsightpartners.com/discount/TIPBT00002082/

Region Coverage:

Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Europe(Turkey, Germany, Russia UK, Italy, France, etc.)

North America(the United States, Mexico, and Canada.)

South America(Brazil etc.)

The Middle East and Africa(GCC Countries and Egypt.)

Stem Cell Banking Market: Competitive Landscape-

Analysts have thoroughly evaluated the competitive landscape in the Stem Cell Banking Market. The report includes the study of key players in the Stem Cell Banking Market. It also outlines the strategic initiatives companies have taken in recent years to keep pace with increasing competition. It also includes an assessment of the financial perspectives of these companies, their research and development plans, and their future business strategies.

Stem Cell Banking Market: Drivers and Restraints-

The comprehensive market assessment of Stem Cell Banking contains a complete explanation of the controls available on the market. Analysts have studied investment in research and development, the impact of changing economies, and consumer behaviour to determine the factors that will drive the market in general. In addition, analysts have attempted to take into account changes in manufacturing and industrial operations that determine product sales in the Stem Cell Banking Market.

This chapter also explains the possible restrictions on the Stem Cell Banking Market. Assess the reasons that could hinder market growth. Analysts have assessed growing environmental concerns and fluctuating raw material costs, which are predicted to dampen the spirit of the Stem Cell Banking Market. However, analysts have also identified potential opportunities that players in the Stem Cell Banking Market can rely on. The chapter on controls, restrictions, threats and opportunities offers a holistic view of the Stem Cell Banking Market.

Key Questions Answered

Answering these types of questions can be very useful for gamers to clear up their doubts as they implement their strategies to grow in the global Stem Cell Banking Market. The report provides a transparent picture of the actual situation in the global Stem Cell Banking Market so that companies can work more effectively. It can be tailored to the needs of readers to better understand the global market for Stem Cell Banking.

Purchase Full Copy of this Report https://www.theinsightpartners.com/buy/TIPBT00002082/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Read the original post:
Expected A Drastic Growth In Stem Cell Banking Market Key Insights Based On Source, Service Type, Application - 3rd Watch News

Recommendation and review posted by Bethany Smith

Leukaemia is the cancer of blood cells. Blood cells originate from HSCs, hematopoietic stem cells, in the bone marrow. Thereafter they undergo maturation process called hematopoiesis. Multipotent hematopoietic stem cells often undergo a process of differentiation while in maturation stage to give rise to progenitor cells of myeloid and lymphoid origin. These Myeloid cells include neutrophils, basophils, monocytes, macrophages, erythrocytes, dendritic cells, eosinophils, and megakaryocytes or platelets. While, Lymphoid cells include B cells, T cells and natural killer cells.

Recently in 2016, Global Leukaemia Therapeutics Market was valued at nearly USD 9.44 billion and is expected to grow at a CAGR of 4.1% between 2017 and 2022, accounting to market worth USD 11.97 billion by end of 2022.

The Final Report will cover the impact analysis of COVID-19 on this industry.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10064998

Normally, the blood forming cells in the bone marrow produce leukocytes, that protects against viruses and bacteria. If these leukocytes get damaged and if they are left untreated they get accumulated in the body and invade in other parts like liver, spleen and central nervous system, hence damaging the entire body. The main reasons causing leukaemia are ionizing radiation, smoking, prior chemotherapy and Down syndrome.

Market Dynamics

Recently in 2016, Global Leukaemia Therapeutics Market was valued at nearly USD 9.44 billion and is expected to grow at a CAGR of 4.1% between 2017 and 2022, accounting to market worth USD 11.97 billion by end of 2022.

Global Leukaemia Therapeutics market is majorly driven by the growing number of incidences of target disease across the globe. Also, development of novel agents, advancements in technology and combination therapy with reduced side effects and better survival conditions are some other key factors that drives the Leukaemia Therapeutics Market.

However, the high cost of combination therapies and clinical trials coupled with post-treatment complications, adverse events and side effects are the major constraints that limit the growth of the market.Nevertheless, initiatives like increasing focus on healthcare and personalized medicine along with huge govt. investment & R&D in anti-leukaemia therapeutics research are sure short to boost the market growth in the near future.

Market SegmentationGlobal Leukaemia Therapeutics Market can be segmented as follows :Segmentation by TypeChronic leukaemiaChronic myeloid leukaemiaChronic lymphatic leukaemiaAcute leukaemiaAcute myeloid leukaemiaAcute lymphatic leukaemia

Request For Full Report:https://www.kennethresearch.com/sample-request-10064998

Segmentation by TherapyBiological TherapyRadiation therapyChemotherapyTargeted therapy

Regional/Geographic AnalysisEurope, North America, Latin America, Asia-Pacific, Middle East & Africa are key market segments of global Leukaemia Therapeutics. North America is the leading region and is anticipated to remain one in the near future, over the forecast period. Demand for leukaemia therapeutics was highest in North America especially in the U.S attributing to increasing geriatric population and increased number of cases. While, Asia Pacific region along with Middle East, Africa and Latin America is expected to grow at moderate pace.

Key Players

The key players in global leukaemia therapeutics market includeF. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Teva Pharmaceuticals, Novartis International AG., GlaxoSmithKline plc., Genzyme Corporation, AbbVie Inc. and others.

About UsKenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation.

Contact UsKenneth ResearchEmail:[emailprotected]Phone:+1 313 462 0609

Visit link:
Leukaemia Therapeutics Market is expected to grow at a CAGR of 4.1% between 2017 and 2022 - WaterCloud News

Recommendation and review posted by Bethany Smith

Chicago, United States: The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the globalWithania Somnifera Extract Market. It includes Porters Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Withania Somnifera Extract Market. We have provided deep analysis of the vendor landscape to give you a complete picture of current and future competitive scenarios of the global Withania Somnifera Extract market. Our analysts use the latest primary and secondary research techniques and tools to prepare comprehensive and accurate market research reports.

Top Key players cited in the report: Life Extension, Taos Herb Company, General Nutrition Centers, Jarrow Formulas, Huge Mountain, Organic India, The Vitamin Shoppe, NOW Foods, Solgar, Piping Rock, Swanson

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart)

Each segment of the global Withania Somnifera Extract market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Withania Somnifera Extract market through leading segments. The regional study of the global Withania Somnifera Extract market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Withania Somnifera Extract market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Withania Somnifera Extract Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Withania Somnifera Extract market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Withania Somnifera Extract market participants in the past few years to remain ahead of the competition.

Global Withania Somnifera Extract Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Withania Somnifera Extract market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Withania Somnifera Extract market.

The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Request For Customization @https://www.reporthive.com/request_customization/2311790

Report Highlights

Comprehensive pricing analysis on the basis of product, application, and regional segments

The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the global Withania Somnifera Extract market

Deep insights about regulatory and investment scenarios of the global Withania Somnifera Extract market

Analysis of market effect factors and their impact on the forecast and outlook of the global Withania Somnifera Extract market

A roadmap of growth opportunities available in the global Withania Somnifera Extract market with the identification of key factors

The exhaustive analysis of various trends of the global Withania Somnifera Extract market to help identify market developments

Table of Contents

Report Overview:It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Withania Somnifera Extract market segments by application, study objectives, and years considered.

Global Growth Trends:There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Withania Somnifera Extract Market Share by Manufacturer:Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type:It includes analysis of price, production value market share, and production market share by type.

Market Size by Application:This section includes Withania Somnifera Extract market consumption analysis by application.

Profiles of Manufacturers:Here, leading players of the global Withania Somnifera Extract market are studied based on sales area, key products, gross margin, revenue, price, and production.

Withania Somnifera Extract Market Value Chain and Sales Channel Analysis:It includes customer, distributor, Withania Somnifera Extract market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Get Sample Copy of this report:https://www.reporthive.com/request_sample/2311790

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Visit link:
COVID-19 Impact on Withania Somnifera Extract Market Development, Future, Importance and Forecast Report 2020 to 2025: Life Extension, Taos Herb...

Recommendation and review posted by Bethany Smith

Instead of producing oil offshore Newfoundland, the Terra Nova FPSO may soon become a longer-term fixture in Conception Bay, or dockside at a port like Bay Bulls.

That's not a good scenario for Newfoundland and Labrador's oil industry, the hundreds of workers linked to the aging oil production vessel, or a provincial treasury that can ill afford to lose the couple-hundred-million in oil royalties that typically flow from the Terra Nova each year.

The Terra Nova oil field was the second of four in the offshore to begin production, with first-oil from the Terra Nova FPSOreported in January 2002.

Since then, Suncor Energy and its partners have pumped more than 420 million barrels of oil from the field, nearly twice as much as the White Rose field, though well short of the more than 1.1 billion barrels at Hibernia.

Terra Nova averaged nearly 30,000 barrels of production each day in 2018 and 2019.

The oil companies long ago recovered their initial investment in the project, and as a result, oil royalties from the Terra Nova are the most lucrative for the province on a per capita basis.

But the vessel is near the end of its life, and it has been anything but smooth sailing for the past six months.

Now a deluge of ill winds have combined to cripple the operation, and derail a costly plan to overhaul the vessel to add adecade to its life and produce up to 80 million more barrels of oil.

There's a very real possibility that, once it leaves this summer, the Terra Nova FPSO might not return to the Grand Banks for up to two years. That's left workers on edge, with their futures very much in limbo.

So how did we get here?

The Terra Nova is showing its age. That's one factor. A global pandemic has also dealt a devastating blow to the world oil industry, with nearly every form of transportation practically seized up. And a production war between Saudi Arabia and Russia earlier this year drove stockpiles to the brim.

Newfoundland and Labrador is not exempt from these world events despite the coveted light, sweet crude that is produced in our offshore and the industry is now in crisis mode.

The challenges for the Terra Nova began in December, when theboard that regulates the offshore industry ordered a stop to production because of a safety deficiency related to fire suppression. Further inspections found more problems.

Suncor and the Canada-Newfoundland and Labrador Offshore Petroleum Boardhave been in talks for months, trying to reach an agreement that would allow the vessel to resume production.

Those talks recently broke down, with the partners unwilling to invest the estimated $150 million to $200 million required to get approval to operate from the board, according to sources.

And a six-month, $600-million plan to sail the Terra Nova to a dockyard in Spain last month for life-extension overhaul is in limbo because of the COVID-19 pandemic.

It's work that cannot be done in this province or Canada, for that matter sayinsiders, and missing the window of opportunity in Spain is a setback.

"We do not have an approved alternative for the asset life extension project," confirmed Suncor in a statement Friday.

What's more, the vessel's all-important certificate of fitness expires next summer, and certifying authorities likeLloyd's Register North Americawill demand a major refit before the Terra Nova resumes production.

So while plenty is still unknown, this is certain: the Terra Nova will soon be disconnected from its subsea production systemsand will sail into an uncertain future.

That's a blow for the province, on many levels.

According to a benefits report released by Suncor for the fourth quarter of 2019, atotal of 853 people were working with the Terra Nova project at the end of last year, and more than 90 per cent of them were residents of Newfoundland and Labrador.

What will become of those workers?

"Our people are very important to us.When a final decision is made on the path forward, we will work to understand the staffing requirements to support the plan and keep our team informed as decisions are made," Suncor stated in an email Friday.

The removal of the Terra Nova will also be felt by the supply and service sector,from helicopter and supply ship services to catering and personal protective equipment sales.

For the fourth quarter of 2019, there were more than 1,500 purchase orders related to the project, valued at $24 million. Nearly $16 million of those purchases were made from companies with locations in Newfoundland and Labrador.

It's little wonder the N.L. oil and gas industries association and its 600 members arein panic mode. Many of Noia's members have slashed jobs, and some have closed up shop, according to CEO Charlene Johnson.

But the union says it will continue to press for a solution, including a quicker return to production.

"We're trying to get this reversed. There is still some fight left in us yet," said Dave Mercer, president of Unifor Local 2121, which represents 400 workers involved with the Terra Nova.

Read more from CBC Newfoundland and Labrador

Original post:
How a pandemic and production war thrashed one of N.L.'s 4 producing oil fields - CBC.ca

Recommendation and review posted by Bethany Smith

NOTE FOR 2020 READERS: This is the eleventh in a series of open letters to the next century, now just 80 years away. The series asks: What will the world look like at the other end of our kids' lives?

Dear 22nd Century,

For all the pain, grief and economic hardship the 2020 coronavirus pandemic has sown, a handful of green shoots seem to have taken root in its blighted soil.

Green being the operative word, because many of these developments could be a net positive for the planet. In lockdown, many of us are seeing what our cities look like without smog. Office workers are experiencing office life without the office; just last week, Twitter announced that most of its employees could work from home forever, while much of Manhattan is reportedly freaking out about what could happen to commercial real estate. Thousands of companies just discovered they can still function, and maybe even function better, when they dont chain employees to desks or force them to make a soul-crushing, carbon-spewing commute 10 times a week.

And what do more people do when theyre spending more time at home? Well, if youre like my wife, you start literally planting green shoots. Our house is filling up with them as I write this: lettuce, chard, tomatoes, basil, strawberries, to name the first five shoots poking out of dozens of mason jars now taking up residence on every windowsill. Shes hardly alone; garden centers and seed delivery services are reporting as much as 10 times more sales since the pandemic began. Even the mighty Wal-Mart has sold out of seeds. Ifviral Facebook postsand Instagram hashtags are any guide, pandemic hipsters have moved on from once-fashionable sourdough starters to growing fresh fruit and veg.

Another one of our cyclical back to the land movements seems to be underway, just like during the 1960s and the Great Depression before that. Only this time, we dont need land. We dont need soil. We dont need pesticide of any kind. We dont even need natural light. Thanks to giant leaps forward in the science of hydroponics and LED lighting, even people in windowless, gardenless apartments can participate in the revolution. With a number of high-tech consumer products on the way, the process can be automated for those of us without green thumbs.

In previous letters Ive discussed the inevitable rise of alternative meat, a process that has been acceleratedby the pandemic. I talked about the smaller, more nutritious plant-based meals we're going to need for life extension; I assumed such meals would be delivered by drone. But now I see a future with no food deserts, in which every home is filled with rotating space-station-like hydroponics run by artificial intelligence a cornucopia of push-button farming providing the side salad to your plant-based meat.

Even if you dont grow your own, robot-run vertical farms and community agrihoods, now springing up everywhere, will make amazing-tasting produce abundant and cheap. The locavores of our era like to boast about their 100-mile diet. Yours will look more like a 100-yard diet.

Its worth remembering that it wasnt supposed to be this way. The 2020s, in fact, is when we were slated for starvation, food riots, and big business quietly processing our corpses into food.

Thats the plot of the 1973 movie Soylent Green, set in the year 2022. Fruit and veg have all but vanished. In one scene, Charlton Heston's detective hero smuggles home a single tomato and a wilted stick of celery, enough to reduce his roommate Sol (Edward G. Robinson) to tears. On the other end of the future, in a lighter but equally depressing vein, the 2006 comedy Idiocracy showed the Americans of 2500 running out of crops because they couldnt figure out that water, not "Brawndo" (a spoof on colorful sports drinks), is what plants crave.

But these dismal future visions are receding thanks to the science of hydroponics which dates back to the 19th century, no matter its present-day association with growing marijuana. By the 1930s, wed figured out that what plants crave is surprisingly minimal: nitrogen, a handful of minerals, something to anchor the roots like rock wool or coconut husks, and H2O. Early hydroponic farms helped feed U.S. soldiers as they hopped through the Pacific during World War II.

Minimalist methods multiplied, and are still multiplying. Were tweaking the spectrum of LED lights for maximum growth, and figuring out ways to use progressively less water and nutrients. My wifes mason jar seedlings use something called the Kratky method, where you don't even need to change the water. It turns out this method wasinvented by a Hawaiian scientist as recently as 2009. And its the closest science has yet given us to a free lunch.

Im nowhere near as excited by hydroponics as my wife is. But during our quarantine time, even my head has been turned by the Rotofarm, which Ive come to think of as the iPhone of gardening. Its a beautiful device inspired by NASA research on growing plants in space. It uses anti-gravity literally, when the wheel rotates around its LED light source and the plants are hanging upside down to grow plants faster. A magnetic cover reduces the glare and increases the internal humidity. You manage it via an app.

Humankinds oldest technology turns out to be the most efficient use of space for growing plants; even in this 15-inch-wide wheel, you can really pack them in. At the bottom of the wheel, plants dip their roots into the water and nutrient tanks. An owners only job is to refill the tanks every week or so, and to snip off their dinner with scissors a few weeks after germination. Some leafy greens, like my favorite salad base arugula, can be regrown without replanting.

Still, to be fully self-sufficient, a future apartment is going to need to have multiple Rotofarm-style devices on the go at once but theyre designed to live anywhere you can plug in, on coffee tables, on desks, on walls, as eye-catching as artwork.

The main problem with the Rotofarm: It isnt actually on sale yet. It feels like weve done everything in reverse, Rotofarm creator Toby Farmer said when I reached him via video chat from his home in Melbourne. Weve got the patents, weve got the design awards, weve got the customers. Now we need to finish the prototypes. (One key tweak: reducing Rotofarms energy requirements, which as it stands could double many users household electricity bills.)

Still, orders have come from as far afield as Japan and the Netherlands, from retailers and regular users alike. Farmers biggest regret: When Ron Howards production company called, hoping to use eight Rotofarms in an upcoming Nickelodeon show set in space, Farmer didnt have enough to spare.

Rotofarm has been in the works for a few years, but acrowdfunded Indiegogocampaign that closed last month exceeded its $15,000 goal by a third of a million dollars. Farmer, despite his name, had no experience in this area; just 23 years old, he had been a web designer since the age of 12. But hes scaling up fast, hiring teams in LA and Singapore, soaking up their knowledge (he was keen to assure me hed hired a lot of 40-somethings for this very reason).

After a projected 2021 release date, Rotofarms business model involves making money on proprietary seed pods though Farmer admits that theres a DIY aspect where customers can make their own. His hope is that official Rotofarm pods will be competitive because theyll have fewer germination failures, but he'd rather see a world where more people own the device itself. In that spirit, hes making it modular the LED light bar can be upgraded separately, for example, rather than making customers buy a whole new device. (As for cost, Farmer says he can't comment yet though Indiegogo backers were able to secure one for $900 a pop.)

Might the Rotofarm fail? Of course, just like any other crowdfunded project. Much depends on its price point, as yet unannounced. But its far from the only next-level, set-it-and-forget-it hydroponic station taking aim at your kitchen. Theres a Canadian Kickstarter called OGarden that also grows food on a wheel, albeit a much larger wheel. The OGarden was funded in its first six minutes online and is set to cost around $1,000 per unit. Theres Farmshelf, a $4,900 pre-order hydroponic device that looks like a see-through refrigerator, backed by celebrity chef Jose Andres. Users will pay a $35 monthly subscription to get all the seeds they need.

One of these models is the future; maybe all of them are. Right now, these are high-end devices aimed at early adopters (and restaurants, which get a lot of benefit out of showing off how fresh their produce is as customers walk in). But with scale, with time, and with the growing desire for grow-your-own food that Rotofarm and its brethren have revealed, they will get cheaper and more widespread.

After all, the first Motorola cellphone, in 1983, cost $4,000. It looked like a brick and had 30 minutes of talk time. Now sleek, supercomputer-driven smartphones are accessible to pretty much everyone. The same process will happen in home hydroponics.

Give it 80 years, and I can see apartments with built in hydroponic farms provided as a standard utility, much as a fridge is seen as a standard feature today. As more humans move to urban environments two out of every three people will be in cities by 2050, according to the latest UN estimate the need for such devices will only grow.

We strongly believe the future of gardening is indoor gardening and more individual gardens, OGarden CEO Pierre Nibart told us last year. Stopping mass agriculture and starting to produce their own little stuff at home. He said this while demonstrating his family's daily OGarden routine: His kids harvest most of what they need for dinner from the spinning wheel.

Mass agriculture hasnt exactly covered itself in glory where produce is concerned. And in the post-coronavirus age, we are surely going to become less tolerant of the disease its intensive farming methods have caused.

Food poisoning caused by romaine lettuce, which makes up a quarter of all leafy greens sold in the U.S., has become depressingly familiar. The 2018 E coli outbreak was the worst it sickened 240 people in 37 states, hospitalized almost half of them, and killed five. But the CDC has logged 46 E coli outbreaks since 2006, and says that every reported case of infection is likely matched by 26 unreported ones. And theyre only just starting to figure out the most likely cause: groundwater contaminated by nearby cattle manure. There could also be infection from passing birds, another major vector of bacteria.

Never mind the wet markets of Wuhan that likely caused the coronavirus pandemic. Were already sickening ourselves on the regular with a problem that is baked directly into our food system and its affecting vegans as much as meat eaters.

I have no doubt youll look at our barbaric farming methods and shake your heads. Why did they use so much water? Why did they transport produce an average of 1,500 miles? Why did they grow it outdoors, where its vulnerable to pests, and then use pesticides that had to be washed off? Why did they think triple washing did anything to remove bacteria (it doesnt)? Why did they bother using soil, for goodness sake? Didnt they know what plants crave?

The force of legacy agriculture is strong, but an increasing number of companies are figuring out a better way: the vertical farm, so named because they can stack hydroponic produce in shelves or towers. As I write this, there are more than 20 vertical farm operations being constructed and tested around the country. They use around 90 percent less water than regular soil farms, can grow roughly 10 times more food per acre than regular soil farms, and using precision software they can harvest their produce 30 percent faster than regular soil farms.

Sure, theyre spending more on electricity, but theyre also spending nothing on pesticide. The economics seem irresistible.

Last year, less than 20 miles from where I write this, in highly urbanized South San Francisco, a company called Plenty unveiled its flagship operation, a vast vertical farm named Tigris. Its sheer scale invites the correct usage of Californias favorite word, awesome. Tigris can grow a million plants at once, harvesting 200 of them every minute. With $226 million in funding, Plenty says it has already farmed 700 varieties of produce. Right now, the cost to consumers is comparable to non-hydroponic products (I can get their baby arugula at my nearest Safeway for a dollar an ounce); in the long run, it should be cheaper.

And they are far from the only success story. A Chinese startup, Alesca Life, is turning disused parking lots into vertical farms as well as selling plug-and-play shipping container farms. Back in Silicon Valley, a company called Iron Ox is developing robot arms for indoor farmwork. The future looks green, and bountiful, and mostly automated (which is yet another reason youre going to need Universal Basic Income).

Which is not to say that outdoor agriculture is going away completely; its just going to shrink to the size of a community garden. Thats the basis of new urban developments called agrihoods, or multihome communities centered around a professionally managed farm; a just-published book called Welcome to the Agrihoodrepresents their first directory.

Rooftop organic farms, urban allotments: These are places where city dwellers can connect to the land and feel the satisfaction of nurturing their seeds from scratch. Soil may not be necessary to feed us, but sometimes its good to feel the dirt in your fingers. Similarly, farmer's markets are unlikely to go away. In a world where grocery stores are increasingly becoming delivery centers for services like Instacart, there will still be value in meeting and buying direct from the growers of high-end produce.

With big agribusiness heading indoors, with our apartments growing much of what we need and vertical farms providing backup in every city, well also be able to let most of our present-day farmland go fallow. That in itself should take care of a chunk of climate change, considering the amount of carbon-soaking vegetation that springs up on fallow land. Lab-grown and plant-made meat will remove the need for those disease-ridden feedlots. Aquaponics, another discipline where the science is expanding by leaps and bounds, may even let us grow our own fish for food, reducing the strain on our overfished oceans.

No doubt it wont be all smooth sailing. No doubt we, as humans, will stumble upon fresh ways to mess up the planet and make life worse. But from where Im sitting, surrounded by soilless germinating jars, the future looks very green and nutritious indeed.

Yours in leafy goodness,

2020

View original post here:
The indoor farm revolution - Mashable SE Asia

Recommendation and review posted by Bethany Smith

A dual-Ovenable tray is useful for the purpose of supporting a food product. The tray comprises of a sheet having first & second layers comprising one or more polyamides. The first layer of the sheet forms tray inside surface. Where the first layer has got a melting point, the second layer has the melting point of at max about 210 C. & at least 20 C. greater than melting point of the first layer. Where the first layer has a glass transition temperature of less than about 120 C. measured at a 50% relative humidity, the second layer has a melting point of at least about 210 C.

Request For Report Sample:https://www.trendsmarketresearch.com/report/sample/3025

Most plastics deform at the high temperatures but the dual ovenable trays and containers can resist when the heat applications are very high and are bakeable in any conventional or microwave oven without getting melted or without de-forming. They keep the oven clean & preserve the food contained within it. Material used for the dual ovenable trays and containers provides outstanding shelf life extension & appearance appeal.

In terms of material type, thedual-ovenable trays & containers marketis bifurcated into paperboard, C-PET, A-PET, PP, PE, and others. The C-PET segment is estimated to dominate the market throughout forecast period having an estimated market share of around 88.7% in 2018. The PP segment is estimated to register the CAGR of around 3.3% during forecast period. Paperboard segment is estimated to create an incremental dollar opportunity of US$ 29 Mn during forecast period. Based on material, the CPET segment accounted for the considerable market share during forecast period.

CPET is the most adaptable option for the ready meals attributed to easily seal & most affordable. CPET trays withstand temperatures ranging from -40 to +220 C. In terms of geography, North America is expected to have largest market share during forecast period in the region due to increase in the consumption of ready-to-eat meals. Elisabeth Skoda explores recent innovations in the area of ovenable and microwavable packaging.

Terinex has introduced the new Q-Tex film, a heat sealable PET mono layer HD printed food grade ovenable film, which is suitable for freezer, microwave and oven usage. The Q-Tex film has one layer instead of the two found in laminate alternatives, therefore offering material reduction and easier recyclability.

Some of the key players profiled in this market include Bemis Company, Inc., Sealed Air Corporation, Dupont Teijin Films, Genpak, LLC, Evergreen Packaging, Inc., Sonoco Products Company, Oliver Packaging & Equipment Co., MCP Performance Plastic Ltd, CiMa-Pak Corporation, PinnPACK Packaging LLC, PAC Food Pty Ltd., Sanplast Ltd, Pactiv LLC, Plastic Package, Inc.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/dual-ovenable-trays-and-containers-market

See the rest here:
Dual-Ovenable Trays & Containers Market Increasing Demand with Key Players COVID-19 Impact Analysis - Cole of Duty

Recommendation and review posted by Bethany Smith

Global Male Hypogonadism Market: Snapshot

Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in severity from person to person. It is often the cause of partial or complete infertility. There are multiple forms of male hypogonadism and even more ways to classify them. Most endocrinologists commonly classify male hypogonadism on the basis of the level of defectiveness of the male reproductive system.

In many cases, doctors also measure the level of gonadotropins to classify a patient between primary and secondary male hypogonadism. Primary male hypogonadism refers to the cause of the condition being due to defective gonads. There are different types of primary male hypogonadism, including Turner syndrome and Klinefelter syndrome. Secondary male hypogonadism is caused by defects in pituitary or hypothalamic glands. They include Kallmann syndrome and hypopituitarism.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1127

Global Male Hypogonadism Market: Overview

Male Hypogonadism refers to a clinical condition, wherein the testes fail to produce enough testosterone leading to delayed puberty or incomplete development. The condition is related to impaired development of muscle mass, development of breast tissues, impaired body hair growth, and lack of deepening of the voice.

The male Hypogonadism market can be segmented by therapy, type, drug delivery, and geography.

The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities.

Global Male Hypogonadism Market: Trends and Opportunities

The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the markets growth.

However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lipral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the markets growth.

Global Male Hypogonadism Market: Regional Overview

The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe.

Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism.

Major Companies Mentioned in Report

Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring.

Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/male-hypogonadism-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

Excerpt from:
Male Hypogonadism Market Future Aspect Analysis and Current Trends by 2017 to 2025 - 3rd Watch News

Recommendation and review posted by Bethany Smith

(WZAW) -- The current pandemic has upended so many aspects of everyday life, but for people considering pregnancy or already pregnant, those changes can feel even more overwhelming. With medical appointments delayed or moved to telemedicine sessions, many women may feel more uncertainty about their healthcare.

On Wednesday, genetic counselor and womens health expert Julia Wilkinson joined NewsChannel 7 at 4 to share specific steps you and your partner can do during this time while youre at home to make sure youre ready for your next appointment, either via telemedicine or in person.

The first thing Wilkinson talked about was the importance of doing your research. Gather information from both your and your partners relatives to learn about your familys health history.

Find out if theres anything in that history that you might be concerned about for your own health or for the health of your future children, she said.

Also, she said to track your menstrual cycles if youre not already doing so. Also consider taking an ovulation test or fertility test if theyve been irregular.

Wilkinson said you should also be gathering your medical records into one location, especially if youre been seeing different physicians in the last five years. Contact their offices to obtain your medical records. If not, make a list of any health events or significant medical activities. Its also a good way to be sure youre up to date on vaccines.

Lastly Wilkinson said that genetic testing is incredibly important for everyone to have. Parents may have genetic conditions that can be passed onto unborn children. Leading health organizations recommend carrier screening be offered to all women who are pregnant or planning on becoming pregnant. Tests kits are available online and can be done right at home.

That way you can do everything you need to do to prepare for that next appointment, she added.

For more information visit http://www.invitae.com

Go here to read the rest:
Family planning during the COVID-19 pandemic - WSAW

Recommendation and review posted by Bethany Smith

Imagine if one company held a patent covering all methods of testing for Covid-19 antibodies. The company could charge monopoly prices for its tests and prohibit competitors including non-profit and university labs from manufacturing or administering their own. If the company made itself the countrys sole supplier, it would struggle to meet demand. The company would profit, but Americans would face waiting lists, confusion and inequitable access and the virus would keep spreading.

Would a patent holder ever exploit an outbreak of life-threatening infectious disease in this way? Yes. In 2001, the United States faced a credible threat of an anthrax outbreak, yet Bayer refused to license its patents on ciprofloxacin (Cipro), the most effective antibiotic treatment for anthrax, to competitors, even as Bayer itself struggled to supply the nations antibiotic stockpile.

It may seem outlandish to imagine one patent creating a wide-ranging monopoly on diagnostic testing, but it happened. In the 1990s and 2000s, biotech companies obtained and enforced broad patents on medical diagnostics that gave them near-total control of testing for particular conditions. One company obtained patents on methods of diagnosing people at high risk of developing breast cancer and attempted to eliminate testing at competing laboratories by sending cease-and-desist letters; another became the sole provider of genetic testing for many neurological and endocrine conditions, including muscular dystrophy and Alzheimers disease.

By 2011, the American Medical Association submitted an alarmed amicus brief to the US supreme court, lamenting that [i]t is hard to imagine how the clinical diagnostic community will continue to provide quality patient care and how physicians will continue to practice medicine in an ethical and effective manner under a patent regime that permits broad patents on the bodys natural responses to illness and medical treatment.

The supreme court listened. Between 2012 and 2014, in a trio of important cases Mayo, Myriad and Alice it confirmed that if a patent is directed to an abstract idea, natural phenomenon or natural law, it must claim something new and attributable to the inventor an inventive concept to become eligible for patent protection. A patent cant broadly claim a fundamental building block of knowledge like the human bodys antibodies to Covid-19 and tack on ubiquitous, conventional technology like using a needle to draw a blood sample containing those antibodies. These supreme court decisions helped restore patent laws traditional balance between inventors incentives and public access to technology.

The United Statess innovation economy has grown under Mayo, Myriad and Alice, with benefits to healthcare and not just diagnostic testing. For example, in 2013, Justus Decher developed a telehealth product that enables patients to consult with doctors remotely. A few years later, Decher was accused of infringing an older patent so broad it covered the basic idea of remotely consulting patients even by telephone. Fortunately, a court invalidated the patent under the supreme courts Mayo and Alice precedents. Dechers and other telehealth technologies have provided an important lifeline in the Covid-19 pandemic.

Pro-patent voices are now using the Covid-19 crisis to push the Coons-Tillis bill

Freed from overbroad patents on fundamental knowledge, we see an explosion of efforts to build and disseminate new tools to fight Covid-19, including 3-D printed and open source masks and ventilators and clinical trials on dozens of potential treatments and vaccines. While the US lags on deploying diagnostic testing, inventors are busily inventing: the FDA has authorized dozens of different Covid-19 tests. Some inventors may be motivated by the patent incentive companies can still get patents, just within limits. But much is driven by altruism, love of science and the reputation that comes from inventing something that saves millions of lives. Today, no one company monopolizes Covid-19 testing, and all benefit.

Yet some patent holders and their allies are unwisely threatening this balance. Last year, with support from the largest pharmaceutical and biotech industry trade groups, Senators Chris Coons and Thom Tillis proposed a bill that would undo Mayo, Myriad, and Alice, expanding limits on patent eligibility. Pro-patent voices are now using the Covid-19 crisis to push the Coons-Tillis bill, asserting that broad patents on now-patent-ineligible subject matter are necessary to incentivize invention of anti-Covid technologies, especially diagnostic tests. That ignores evidence that the biggest problems we face are global shortages of unpatented basic supplies like nasal swabs and a failure of federal government coordination, not a shortage of inventive activity.

Congress should reject these efforts to undo the traditional balance and expand the scope of patent eligibility. The current legal standard may not be perfect, but it is working. In the Covid-19 crisis, Congress should focus instead on policies that give healthcare workers, other essential workers, patients, and all Americans the resources they need.

Chris Morten is the supervising attorney at NYU Laws Technology Law & Policy Clinic and a fellow at NYU and Yale Law Schools. Alex Moss is a staff attorney at the Electronic Frontier Foundation, specializing in intellectual property

Follow this link:
Could a patent get in between you and a Covid-19 test? Yes - The Guardian

Recommendation and review posted by Bethany Smith

Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global Direct-Access Genetic Testing market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global Direct-Access Genetic Testing market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global Direct-Access Genetic Testing market.

Key companies operating in the global Direct-Access Genetic Testing market include : , 23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full Genomes Direct-Access Genetic Testing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1698253/covid-19-impact-on-global-direct-access-genetic-testing-market

Segment Analysis

The segmental analysis will help companies to focus on high-growth areas of the global Direct-Access Genetic Testing market. In order to broaden the overall understanding of the global Direct-Access Genetic Testing industry, the report has segregated the global Direct-Access Genetic Testing business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.

Global Direct-Access Genetic Testing Market Segment By Type:

, Diagnostic Screening, PGD, Relationship testing Direct-Access Genetic Testing

Global Direct-Access Genetic Testing Market Segment By Application:

, Diagnostic Screening, PGD, Relationship testing Direct-Access Genetic Testing

Competitive Landscape:

It is important for every market participant to be familiar with the competitive scenario in the global Direct-Access Genetic Testing industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Direct-Access Genetic Testing market include : , 23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full Genomes Direct-Access Genetic Testing

Key Questions Answered

Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1698253/covid-19-impact-on-global-direct-access-genetic-testing-market

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Direct-Access Genetic Testing Revenue1.4 Market Analysis by Type1.4.1 Global Direct-Access Genetic Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 Diagnostic Screening1.4.3 PGD1.4.4 Relationship testing1.5 Market by Application1.5.1 Global Direct-Access Genetic Testing Market Share by Application: 2020 VS 20261.5.2 Online1.5.3 Offline1.6 Coronavirus Disease 2019 (Covid-19): Direct-Access Genetic Testing Industry Impact1.6.1 How the Covid-19 is Affecting the Direct-Access Genetic Testing Industry

1.6.1.1 Direct-Access Genetic Testing Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Direct-Access Genetic Testing Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Direct-Access Genetic Testing Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Direct-Access Genetic Testing Market Perspective (2015-2026)2.2 Direct-Access Genetic Testing Growth Trends by Regions2.2.1 Direct-Access Genetic Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Direct-Access Genetic Testing Historic Market Share by Regions (2015-2020)2.2.3 Direct-Access Genetic Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Direct-Access Genetic Testing Market Growth Strategy2.3.6 Primary Interviews with Key Direct-Access Genetic Testing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Direct-Access Genetic Testing Players by Market Size3.1.1 Global Top Direct-Access Genetic Testing Players by Revenue (2015-2020)3.1.2 Global Direct-Access Genetic Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Direct-Access Genetic Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Direct-Access Genetic Testing Market Concentration Ratio3.2.1 Global Direct-Access Genetic Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Direct-Access Genetic Testing Revenue in 20193.3 Direct-Access Genetic Testing Key Players Head office and Area Served3.4 Key Players Direct-Access Genetic Testing Product Solution and Service3.5 Date of Enter into Direct-Access Genetic Testing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Direct-Access Genetic Testing Historic Market Size by Type (2015-2020)4.2 Global Direct-Access Genetic Testing Forecasted Market Size by Type (2021-2026) 5 Direct-Access Genetic Testing Breakdown Data by Application (2015-2026)5.1 Global Direct-Access Genetic Testing Market Size by Application (2015-2020)5.2 Global Direct-Access Genetic Testing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Direct-Access Genetic Testing Market Size (2015-2020)6.2 Direct-Access Genetic Testing Key Players in North America (2019-2020)6.3 North America Direct-Access Genetic Testing Market Size by Type (2015-2020)6.4 North America Direct-Access Genetic Testing Market Size by Application (2015-2020) 7 Europe7.1 Europe Direct-Access Genetic Testing Market Size (2015-2020)7.2 Direct-Access Genetic Testing Key Players in Europe (2019-2020)7.3 Europe Direct-Access Genetic Testing Market Size by Type (2015-2020)7.4 Europe Direct-Access Genetic Testing Market Size by Application (2015-2020) 8 China8.1 China Direct-Access Genetic Testing Market Size (2015-2020)8.2 Direct-Access Genetic Testing Key Players in China (2019-2020)8.3 China Direct-Access Genetic Testing Market Size by Type (2015-2020)8.4 China Direct-Access Genetic Testing Market Size by Application (2015-2020) 9 Japan9.1 Japan Direct-Access Genetic Testing Market Size (2015-2020)9.2 Direct-Access Genetic Testing Key Players in Japan (2019-2020)9.3 Japan Direct-Access Genetic Testing Market Size by Type (2015-2020)9.4 Japan Direct-Access Genetic Testing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Direct-Access Genetic Testing Market Size (2015-2020)10.2 Direct-Access Genetic Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Direct-Access Genetic Testing Market Size by Type (2015-2020)10.4 Southeast Asia Direct-Access Genetic Testing Market Size by Application (2015-2020) 11 India11.1 India Direct-Access Genetic Testing Market Size (2015-2020)11.2 Direct-Access Genetic Testing Key Players in India (2019-2020)11.3 India Direct-Access Genetic Testing Market Size by Type (2015-2020)11.4 India Direct-Access Genetic Testing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Direct-Access Genetic Testing Market Size (2015-2020)12.2 Direct-Access Genetic Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Direct-Access Genetic Testing Market Size by Type (2015-2020)12.4 Central & South America Direct-Access Genetic Testing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 23andMe13.1.1 23andMe Company Details13.1.2 23andMe Business Overview and Its Total Revenue13.1.3 23andMe Direct-Access Genetic Testing Introduction13.1.4 23andMe Revenue in Direct-Access Genetic Testing Business (2015-2020))13.1.5 23andMe Recent Development13.2 MyHeritage13.2.1 MyHeritage Company Details13.2.2 MyHeritage Business Overview and Its Total Revenue13.2.3 MyHeritage Direct-Access Genetic Testing Introduction13.2.4 MyHeritage Revenue in Direct-Access Genetic Testing Business (2015-2020)13.2.5 MyHeritage Recent Development13.3 LabCorp13.3.1 LabCorp Company Details13.3.2 LabCorp Business Overview and Its Total Revenue13.3.3 LabCorp Direct-Access Genetic Testing Introduction13.3.4 LabCorp Revenue in Direct-Access Genetic Testing Business (2015-2020)13.3.5 LabCorp Recent Development13.4 Myriad Genetics13.4.1 Myriad Genetics Company Details13.4.2 Myriad Genetics Business Overview and Its Total Revenue13.4.3 Myriad Genetics Direct-Access Genetic Testing Introduction13.4.4 Myriad Genetics Revenue in Direct-Access Genetic Testing Business (2015-2020)13.4.5 Myriad Genetics Recent Development13.5 Ancestry.com13.5.1 Ancestry.com Company Details13.5.2 Ancestry.com Business Overview and Its Total Revenue13.5.3 Ancestry.com Direct-Access Genetic Testing Introduction13.5.4 Ancestry.com Revenue in Direct-Access Genetic Testing Business (2015-2020)13.5.5 Ancestry.com Recent Development13.6 Quest Diagnostics13.6.1 Quest Diagnostics Company Details13.6.2 Quest Diagnostics Business Overview and Its Total Revenue13.6.3 Quest Diagnostics Direct-Access Genetic Testing Introduction13.6.4 Quest Diagnostics Revenue in Direct-Access Genetic Testing Business (2015-2020)13.6.5 Quest Diagnostics Recent Development13.7 Gene By Gene13.7.1 Gene By Gene Company Details13.7.2 Gene By Gene Business Overview and Its Total Revenue13.7.3 Gene By Gene Direct-Access Genetic Testing Introduction13.7.4 Gene By Gene Revenue in Direct-Access Genetic Testing Business (2015-2020)13.7.5 Gene By Gene Recent Development13.8 DNA Diagnostics Center13.8.1 DNA Diagnostics Center Company Details13.8.2 DNA Diagnostics Center Business Overview and Its Total Revenue13.8.3 DNA Diagnostics Center Direct-Access Genetic Testing Introduction13.8.4 DNA Diagnostics Center Revenue in Direct-Access Genetic Testing Business (2015-2020)13.8.5 DNA Diagnostics Center Recent Development13.9 Invitae13.9.1 Invitae Company Details13.9.2 Invitae Business Overview and Its Total Revenue13.9.3 Invitae Direct-Access Genetic Testing Introduction13.9.4 Invitae Revenue in Direct-Access Genetic Testing Business (2015-2020)13.9.5 Invitae Recent Development13.10 IntelliGenetics13.10.1 IntelliGenetics Company Details13.10.2 IntelliGenetics Business Overview and Its Total Revenue13.10.3 IntelliGenetics Direct-Access Genetic Testing Introduction13.10.4 IntelliGenetics Revenue in Direct-Access Genetic Testing Business (2015-2020)13.10.5 IntelliGenetics Recent Development13.11 Ambry Genetics10.11.1 Ambry Genetics Company Details10.11.2 Ambry Genetics Business Overview and Its Total Revenue10.11.3 Ambry Genetics Direct-Access Genetic Testing Introduction10.11.4 Ambry Genetics Revenue in Direct-Access Genetic Testing Business (2015-2020)10.11.5 Ambry Genetics Recent Development13.12 Living DNA10.12.1 Living DNA Company Details10.12.2 Living DNA Business Overview and Its Total Revenue10.12.3 Living DNA Direct-Access Genetic Testing Introduction10.12.4 Living DNA Revenue in Direct-Access Genetic Testing Business (2015-2020)10.12.5 Living DNA Recent Development13.13 EasyDNA10.13.1 EasyDNA Company Details10.13.2 EasyDNA Business Overview and Its Total Revenue10.13.3 EasyDNA Direct-Access Genetic Testing Introduction10.13.4 EasyDNA Revenue in Direct-Access Genetic Testing Business (2015-2020)10.13.5 EasyDNA Recent Development13.14 Pathway Genomics10.14.1 Pathway Genomics Company Details10.14.2 Pathway Genomics Business Overview and Its Total Revenue10.14.3 Pathway Genomics Direct-Access Genetic Testing Introduction10.14.4 Pathway Genomics Revenue in Direct-Access Genetic Testing Business (2015-2020)10.14.5 Pathway Genomics Recent Development13.15 Centrillion Technology10.15.1 Centrillion Technology Company Details10.15.2 Centrillion Technology Business Overview and Its Total Revenue10.15.3 Centrillion Technology Direct-Access Genetic Testing Introduction10.15.4 Centrillion Technology Revenue in Direct-Access Genetic Testing Business (2015-2020)10.15.5 Centrillion Technology Recent Development13.16 Xcode10.16.1 Xcode Company Details10.16.2 Xcode Business Overview and Its Total Revenue10.16.3 Xcode Direct-Access Genetic Testing Introduction10.16.4 Xcode Revenue in Direct-Access Genetic Testing Business (2015-2020)10.16.5 Xcode Recent Development13.17 Color Genomics10.17.1 Color Genomics Company Details10.17.2 Color Genomics Business Overview and Its Total Revenue10.17.3 Color Genomics Direct-Access Genetic Testing Introduction10.17.4 Color Genomics Revenue in Direct-Access Genetic Testing Business (2015-2020)10.17.5 Color Genomics Recent Development13.18 Anglia DNA Services10.18.1 Anglia DNA Services Company Details10.18.2 Anglia DNA Services Business Overview and Its Total Revenue10.18.3 Anglia DNA Services Direct-Access Genetic Testing Introduction10.18.4 Anglia DNA Services Revenue in Direct-Access Genetic Testing Business (2015-2020)10.18.5 Anglia DNA Services Recent Development13.19 African Ancestry10.19.1 African Ancestry Company Details10.19.2 African Ancestry Business Overview and Its Total Revenue10.19.3 African Ancestry Direct-Access Genetic Testing Introduction10.19.4 African Ancestry Revenue in Direct-Access Genetic Testing Business (2015-2020)10.19.5 African Ancestry Recent Development13.20 Canadian DNA Services10.20.1 Canadian DNA Services Company Details10.20.2 Canadian DNA Services Business Overview and Its Total Revenue10.20.3 Canadian DNA Services Direct-Access Genetic Testing Introduction10.20.4 Canadian DNA Services Revenue in Direct-Access Genetic Testing Business (2015-2020)10.20.5 Canadian DNA Services Recent Development13.21 DNA Family Check10.21.1 DNA Family Check Company Details10.21.2 DNA Family Check Business Overview and Its Total Revenue10.21.3 DNA Family Check Direct-Access Genetic Testing Introduction10.21.4 DNA Family Check Revenue in Direct-Access Genetic Testing Business (2015-2020)10.21.5 DNA Family Check Recent Development13.22 Alpha Biolaboratories10.22.1 Alpha Biolaboratories Company Details10.22.2 Alpha Biolaboratories Business Overview and Its Total Revenue10.22.3 Alpha Biolaboratories Direct-Access Genetic Testing Introduction10.22.4 Alpha Biolaboratories Revenue in Direct-Access Genetic Testing Business (2015-2020)10.22.5 Alpha Biolaboratories Recent Development13.23 Test Me DNA10.23.1 Test Me DNA Company Details10.23.2 Test Me DNA Business Overview and Its Total Revenue10.23.3 Test Me DNA Direct-Access Genetic Testing Introduction10.23.4 Test Me DNA Revenue in Direct-Access Genetic Testing Business (2015-2020)10.23.5 Test Me DNA Recent Development13.24 23 Mofang10.24.1 23 Mofang Company Details10.24.2 23 Mofang Business Overview and Its Total Revenue10.24.3 23 Mofang Direct-Access Genetic Testing Introduction10.24.4 23 Mofang Revenue in Direct-Access Genetic Testing Business (2015-2020)10.24.5 23 Mofang Recent Development13.25 Genetic Health10.25.1 Genetic Health Company Details10.25.2 Genetic Health Business Overview and Its Total Revenue10.25.3 Genetic Health Direct-Access Genetic Testing Introduction10.25.4 Genetic Health Revenue in Direct-Access Genetic Testing Business (2015-2020)10.25.5 Genetic Health Recent Development13.26 DNA Services of America10.26.1 DNA Services of America Company Details10.26.2 DNA Services of America Business Overview and Its Total Revenue10.26.3 DNA Services of America Direct-Access Genetic Testing Introduction10.26.4 DNA Services of America Revenue in Direct-Access Genetic Testing Business (2015-2020)10.26.5 DNA Services of America Recent Development13.27 Shuwen Health Sciences10.27.1 Shuwen Health Sciences Company Details10.27.2 Shuwen Health Sciences Business Overview and Its Total Revenue10.27.3 Shuwen Health Sciences Direct-Access Genetic Testing Introduction10.27.4 Shuwen Health Sciences Revenue in Direct-Access Genetic Testing Business (2015-2020)10.27.5 Shuwen Health Sciences Recent Development13.28 Mapmygenome10.28.1 Mapmygenome Company Details10.28.2 Mapmygenome Business Overview and Its Total Revenue10.28.3 Mapmygenome Direct-Access Genetic Testing Introduction10.28.4 Mapmygenome Revenue in Direct-Access Genetic Testing Business (2015-2020)10.28.5 Mapmygenome Recent Development13.29 Full Genomes10.29.1 Full Genomes Company Details10.29.2 Full Genomes Business Overview and Its Total Revenue10.29.3 Full Genomes Direct-Access Genetic Testing Introduction10.29.4 Full Genomes Revenue in Direct-Access Genetic Testing Business (2015-2020)10.29.5 Full Genomes Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Excerpt from:
Direct-Access Genetic Testing Market which company is the market leader and how much its sales in 2020 and what it's expected sales for the next 5...

Recommendation and review posted by Bethany Smith

A leading research firmZion Market researchadded a recent report on Direct-to-Consumer (DTC) Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026 to its research database. The Direct-to-Consumer (DTC) Genetic Testing comprehensive is perceptible among the most immensely gathered market globally. The Direct-to-Consumer (DTC) Genetic Testing report gives the exchange information and the progressing business chain information in the overall market. The report gives a thought with respect to the advancement of the free market movement of significant players of theDirect-to-Consumer (DTC) Genetic Testing. A noteworthy examination of the market relies upon general plans, which have been of late organized to the investigation of Direct-to-Consumer (DTC) Genetic Testing, is furthermore incorporated into the report.

FREE | Request Sample is Available @https://www.zionmarketresearch.com/sample/direct-to-consumer-genetic-testing-market

Some of the MajorDirect-to-Consumer (DTC) Genetic TestingPlayers Are:

23andMe, Ancestry, Color, EasyDNA, Family Tree DNA, Full Genomes, Genesis HealthCare, Helix, Identigene, Karmagenes, Living DNA

The Direct-to-Consumer (DTC) Genetic Testing report thinks about the present execution of the overall market notwithstanding the novel examples and furthermore a complete bifurcation product, its end-users, applications, and others of the market; additionally, the factual studying report does predictions on the accompanying power of the market reliant on this examination. The Direct-to-Consumer (DTC) Genetic Testing measurable looking over examination incorporates all parts of the overall market, which starts from perception the Direct-to-Consumer (DTC) Genetic Testing, collaborating with customers, and assessing the data of the overall market. Each division of the overall market is researched and isolated dependent on the sort of stock, their applications, and the end-customers.

The worldwide geological [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] analysis of the Direct-to-Consumer (DTC) Genetic Testing plan has furthermore been done cautiously in this report. The dynamic establishment of the overall Direct-to-Consumer (DTC) Genetic Testing depends on the assessment of item circulated in various markets, limitations, general benefits made by every association, and future aspirations. The major application areas of Direct-to-Consumer (DTC) Genetic Testing are also covered on the basis of their implementation. The report gives the ideology about different factors and inclinations affecting the development course of the worldwide Direct-to-Consumer (DTC) Genetic Testing. A review of the impact of the administrative regulations and policies on the Direct-to-Consumer (DTC) Genetic Testing operations is also included in this report. The Direct-to-Consumer (DTC) Genetic Testing report offers a complete analysis of competitive dynamics that are modifying and places the patrons ahead of competitors.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/direct-to-consumer-genetic-testing-market

Promising Regions & Countries Mentioned In TheDirect-to-Consumer (DTC) Genetic TestingReport:

What ourDirect-to-Consumer (DTC) Genetic Testingreport offers:

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/direct-to-consumer-genetic-testing-market

Key Topics Covered:

1. Introduction

2. Executive Summarya

3. Direct-to-Consumer (DTC) Genetic Testing Market Dynamics

4. Global Direct-to-Consumer (DTC) Genetic Testing Competitive Landscape

5. Global Direct-to-Consumer (DTC) Genetic Testing Therapy Type Segment Analysis

6. Global Direct-to-Consumer (DTC) Genetic Testing Therapeutic Area Segment Analysis

7. Global Direct-to-Consumer (DTC) Genetic Testing End-User Segment Analysis

8. Global Direct-to-Consumer (DTC) Genetic Testing Regional Segment Analysis

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/direct-to-consumer-genetic-testing-market

Reason to Buy

Also, Research Report Examines:

Thanks for reading this article;you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Zion Market Researchis an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research244 Fifth Avenue, Suite N202New York, 10001, United StatesTel: +49-322 210 92714USA/Canada Toll Free No.1-855-465-4651

Email:[emailprotected]

Web:https://www.zionmarketresearch.com

Read the original post:
Global Direct-to-Consumer (DTC) Genetic Testing Market with (Covid-19) Impact Analysis: Latest Industry Trends and Insights, 2020-2027 - 3rd Watch...

Recommendation and review posted by Bethany Smith

The report on preimplantation genetic testing market provides a complete assessment of this industry vertical, along with an exhaustive analysis of various market segmentations. The report includes an in-depth, extensive study of this market in tandem with vital parameters that are likely to have an effect on the market commercialization matrix.

Top Companies:

Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/1483

The preimplantation genetic testing Market report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe. The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of preimplantation genetic testing Industry.

The preimplantation genetic testing market report consists of information related to the projected CAGR of the global industry over the forecast period. Also, the numerous technological developments and innovations that are likely to drive the global preimplantation genetic testing market share over the anticipated period are mentioned in the study.

The report covers forecast and analysis for the preimplantation genetic testing market on a global and regional level. The study provides historic data of 2016 to 2019, considering 2019 as the base year, along with a forecast from 2020 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the preimplantation genetic testing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the preimplantation genetic testing market on a global level.

Click here for detailed table of contents: https://www.adroitmarketresearch.com/industry-reports/preimplantation-genetic-testing-market

Global preimplantation genetic testing market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

by Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) and Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism)

In order to give the users of this report a comprehensive view, we have included various industry analysis models in our report and extensively demonstrated the key business strategies and competitive landscape of the preimplantation genetic testing market in our study. Our study also includes an analysis of Porters Five Forces framework for understanding the competitive strategies adopted by various stakeholders involved in the entire value chain of the preimplantation genetic testing market.

Key insights from the preimplantation genetic testing market report: Detailed summary of the regional terrain of the preimplantation genetic testing market. The study offers a succinct overview of the regional topography of the market, while categorizing the same into United States, China, Europe, Japan, and Southeast Asia & India. The report presents data pertaining to market share held by each region, alongside the growth potentials of various geographies. Growth rate attained by each region over the forecast period is depicted in the report.

Do you have any query or specific requirement? Ask to our industry expert at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1483

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Follow this link:
Preimplantation Genetic Testing Market 2019 Industry Outline, Global Executive Players, Interpretation and Benefit Growth to 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith